search results:

ATC
Classification		 Ligand Product Name Approved or not Description ID
- - abagovomab - PMDA - Adaptation Diseases Epithelial ovarian cancer DrugBank -
FDA R 2015
(phase3)		 Pathway - UniProt -
EMA - Remarks In a Phase 3 trial in stage III ・ IV ovarian cancer patients, although the induction of an immune response was confirmed, did not show the expected PFS ・ OS effect (2013).
Development has been discontinued in 2015. 		Target Protein CA125
status reject Source http://jco.ascopubs.org/content/31/12/1554.abstract PDB
    Concomitant Drugs -    
L04AA24 L04A abatacept
アバタセプト		 ORENCIA PMDA 2010/7/23 Adaptation Diseases Rheumatoid arthritis, Idiopathic arthritis DrugBank DB01281
FDA 2005/12/23 Pathway Cell adhesion molecules (CAMs), Toll-like receptor signaling pathway, Intestinal immune network for IgA production, Rheumatoid arthritis UniProt P33681
P42081
EMA 2007/5/21 Remarks Abatacept is used for a treatment of moderate to severe rheumatoid arthritis. Because of some patients taking Avatacept were developing cancer, the relation is under investigation. Target Protein CD80
CD86
status approved Source http://www.rheumatology.org/I-Am-A/Patient-Caregiver/Treatments/Abatacept-Orencia PDB
    Concomitant Drugs -    
B01AC13 B01A abciximab REOPRO PMDA - Adaptation Diseases Myocardial ischemia DrugBank DB00054
FDA 1994/12/22 Pathway Focal adhesion, ECM-receptor interaction UniProt P05106
P08514
EMA 2015/7/17 Remarks Abciximab is used for a treatment of acute coronary syndrome. Target Protein integrin αIIbβ3
status approved Source http://www.abciximab.com/fda_info.html PDB
    Concomitant Drugs -    
- - ABT-414 - PMDA - Adaptation Diseases Glioblastoma Multiforme DrugBank -
FDA phase2 Pathway - UniProt -
EMA - Remarks Safety, biodistribution have been identified in a Phase I trial. Tumor specificity of cancer patients against the tumor has been confirmed. Target Protein EGFR
status phase II Source http://www.investinlife.com/index.php?option=com_content&view=article&id=112
http://www.abbvie.co.jp/about-us/japan-news/2015-news-archive/press-release-20150708-001.html		 PDB
    Concomitant Drugs -    
L04AB04 L04A adalimumab TRUDEXA PMDA - Adaptation Diseases - DrugBank -
FDA - Pathway - UniProt -
EMA 2003/9/1
W		 Remarks The marketing authorisation for Trudexa has been withdrawn at the request of the marketing authorisation holder. Target Protein -
status withdraw Source - PDB
    Concomitant Drugs -    
L04AB04 L04A adalimumab
アダリムマブ		 HUMIRA
ヒュミラ		 PMDA 2008/4/16 Adaptation Diseases Moderate to severe active rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, moderate to severe active Crohn's disease, moderate to severe active ulcerative colitis, moderate to severe Vulgaris psoriasis, moderate to severe active juvenile idiopathic arthritis in children over 4 years and adults DrugBank DB00051
FDA 2002/12/31 Pathway MAPK signaling pathway, Cytokine-cytokine receptor interaction, Apoptosis, TGF-beta signaling pathway, Antigen processing and presentation, Natural killer cell mediated cytotoxicity, Rheumatoid arthritis UniProt P01375
EMA 2003/9/8 Remarks Adalimumab is used in the treatment of infectious diseases as a TNF inhibitor. Sometimes it's used in combination with Rheumatrex. Target Protein TNFα
status approved Source https://www.humira.com/
http://www.rheuma-net.or.jp/rheuma/rm400/rm400_chiryo_seibutsugakutekiseizai.html		 PDB 3WD5
4NYL
    Concomitant Drugs （Rheumatrex）    
L04AB04 L04A adalimumab-atto AMJEVITA PMDA - Adaptation Diseases Moderate to severe active rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, moderate to severe active Crohn's disease, moderate to severe active ulcerative colitis, moderate to severe Vulgaris psoriasis, moderate to severe active juvenile idiopathic arthritis in children over 4 years and adults DrugBank DB00051
FDA 2016/9/23 Pathway MAPK signaling pathway, Cytokine-cytokine receptor interaction, Apoptosis, TGF-beta signaling pathway, Antigen processing and presentation, Natural killer cell mediated cytotoxicity, Rheumatoid arthritis UniProt P01375
EMA - Remarks AMJEVITA is a biosimilar of Humira. It's used as a TNF inhibitor for the treatment of rheumatoid arthritis, infection. Target Protein TNFα
status approved Source https://www.mixonline.jp/Article/tabid/55/artid/54670/Default.aspx PDB 3WD5
4NYL
    Concomitant Drugs -    
- - aducanumab - PMDA - Adaptation Diseases Alzheimer's disease DrugBank -
FDA phase3 Pathway - UniProt -
EMA - Remarks In non-clinical trials and clinical Phase 1b trials, it has been shown to reduce amyloid plaques. The Phase 3 trial has been initiated in August 2015. Target Protein conformational epitope
status phase III Source http://www.alzforum.org/therapeutics/aducanumab PDB
    Concomitant Drugs -    
L04AB03 L04A afelimomab - PMDA - Adaptation Diseases Severe sepsis DrugBank DB04956
FDA phase3 Pathway - UniProt P01375
EMA - Remarks In a Phase 3 trial in sepsis patients with severe, safety and biological activity was confirmed. Afelimomab reduced the all-cause mortality in 28 days and the severity of organ dysfunction in patients with high IL-6 levels. Target Protein TNFα
status phase III Source http://www.ncbi.nlm.nih.gov/pubmed/15640628 PDB
    Concomitant Drugs -    
S01LA05 S01L aflibercept
アフリベルセプト		 EYLEA PMDA 2012/9/28 Adaptation Diseases AMD, CRVO DrugBank DB08885
FDA 2011/11/18 Pathway Cytokine-cytokine receptor interaction, VEGF signaling pathway, Pathways in cancer UniProt P15692
P49763
EMA 2012/11/22 Remarks Aflibercept heal age-related macular degeneration, and the central retinal vein occlusion by inhibiting the macular edema and myopic choroidal neovascularization. Target Protein VEGF-A
PIGF
status approved Source http://investor.regeneron.com/releasedetail.cfm?ReleaseID=625771
http://investor.regeneron.com/releasedetail.cfm?ReleaseID=737801
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002392/human_med_001598.jsp&mid=WC0b01ac058001d124		 PDB
    Concomitant Drugs -    
L01XX44 L01X aflibercept ZALTRAP PMDA - Adaptation Diseases mCRC DrugBank DB08885
FDA 2012/8/3 Pathway Cytokine-cytokine receptor interaction, VEGF signaling pathway, Pathways in cancer UniProt P15692
P49763
P49765
EMA 2013/2/1 Remarks Aflibercept is used to treat metastatic colorectal cancer that experienced a treatment using Oxaliplatin. It's used in combination with FOLFIRI. Target Protein VEGF-A
VEGF-B
PIGF
status approved Source https://www.google.co.jp/url?sa=t&rct=j&q=&esrc=s&source=web&cd=2&cad=rja&uact=8&ved=0ahUKEwjomZnWtN3MAhUiMaYKHU4ADzwQFggsMAE&url=http%3A%2F%2Fwww.sanofi.co.jp%2Fl%2Fjp%2Fja%2Fdownload.jsp%3Ffile%3D3A4B65BC-65F3-4ECA-A4F3-88552413276C.pdf&usg=AFQjCNFFaqEOryJ_z-d6-oEemBK7jbpPBw&sig2=gB67K_saQ6fDwhJDTDpCxw
http://medical.nikkeibp.co.jp/leaf/all/search/cancer/news/201302/528947.html		 PDB
    Concomitant Drugs FOLFIRI    
L04AA15 L04A alefacept AMEVIVE PMDA - Adaptation Diseases Alzheimer's disease DrugBank DB00092
FDA 2003/1/30 Pathway Cell adhesion molecules (CAMs) UniProt P06729
EMA - Remarks Alefacept is used to treat psoriasis to reduce lymphocyte number (T cells). Target Protein CD2
status approved Source http://www.ncbi.nlm.nih.gov/pubmed/12810502
http://www.centerwatch.com/drug-information/fda-approved-drugs/drug/820/amevive-alefacept		 PDB
    Concomitant Drugs -    
L04AA34 L04A alemtuzumab LEMTRADA PMDA - Adaptation Diseases Relapsing remitting multiple sclerosis (RRMS) DrugBank DB00087
FDA 2001/5/7 Pathway caspase-independent apoptotic pathway UniProt P31358
EMA 2013/9/12 Remarks Alemtuzumab is used for a treatment of relapsing-remitting multiple sclerosis (RRMS) in adults. Target Protein CD52
status approved Source http://en.sanofi.com/Images/33844_20130917_EU-LEMTRADA_en.pdf PDB
    Concomitant Drugs -    
L04AA34 L04A alemtuzumab
アレムツズマブ		 CAMPATH (MabCAMPATH)
マブキャンパス		 PMDA 2014/9/26 Adaptation Diseases Chronic lymphocytic leukemia (CLL) DrugBank DB00087
FDA 2001/5/7 Pathway caspase-independent apoptotic pathway UniProt P31358
EMA 2001/7/6
W		 Remarks Alemtuzumab is a remedy for chronic lymphocytic leukemia (CLL). Target Protein CD52
status approved Source http://www.tandfonline.com/doi/abs/10.1586/14737140.2.1.23 PDB
    Concomitant Drugs -    
C10AX14 C10A alirocumab
アリロクマブ		 PRALUENT
プラルエント		 PMDA 2016/7/4 Adaptation Diseases Hyper-cholesterolemia DrugBank DB09302
FDA 2015/7/24 Pathway non-saturable proteolytic pathway UniProt Q8NBP7
EMA 2015/9/23 Remarks Alirocumab is used for a treatment of primary hypercholesterolemia. Target Protein PCSK9
status approved Source http://newsroom.regeneron.com/releasedetail.cfm?ReleaseID=942030
http://www.who.int/medicines/publications/druginformation/issues/WHO_DI_29-4_ATC-DDD.pdf		 PDB
    Concomitant Drugs -    
C10AX14 C10A altumomab Indium In 111 altumomab pentetate PMDA - Adaptation Diseases - DrugBank -
FDA - Pathway - UniProt -
EMA - Remarks - Target Protein -
status withdraw Source http://www.mdpi.com/toc/htmlview/tableview?i=t1-cancers-03-03279&m=cancers-03-03279-manuscript&v=t&u=/2072-6694/3/3/3279 PDB
    Concomitant Drugs -    
- - ALX-0061 - PMDA - Adaptation Diseases Rheumatoid arthritis, Systemic lupus erythematosus DrugBank -
FDA phase2 Pathway - UniProt -
EMA - Remarks Clinical concept has been demonstrated in a Phase 2a trial. A Phase 2b study has been initiated. Target Protein IL-6R
status phase II Source http://www.ablynx.com/rd-portfolio/clinical-programmes/alx-0061/ PDB
    Concomitant Drugs -    
- - amatuximab - PMDA - Adaptation Diseases Cancer DrugBank -
FDA phase2 Pathway - UniProt -
EMA - Remarks In a Phase 2 trial, it failed to improve progression-free survival period of MPM patients, however, objective response rate was good. Currently, a randomized, double-blind, placebo-controlled study is performed. Target Protein IgG1
status phase II Source http://www.morphotek.com/pipeline/Amatuximab.aspx PDB
    Concomitant Drugs -    
- - anifrolumab - PMDA - Adaptation Diseases SLE DrugBank -
FDA phase3 Pathway interferon pathway UniProt -
EMA - Remarks Clinical concept has been demonstrated in a Phase 2 trial. A Phase III trial has been initiated in July 2015. Target Protein Type I IFNR1
status phase III Source http://www.biocentury.com/biotech-pharma-news/products/2015-11-16/what-medimmune-is-doing-to-increase-odds-of-phase-iii-sle-success-for-anifrolumab-a03
http://www.techtimes.com/articles/105396/20151111/astrazeneca-lupus-drug-anifrolumab-impresses-in-mid-stage-trial.htm		 PDB
    Concomitant Drugs -    
V09IA06 V09I arcitumomab CEA-SCAN PMDA - Adaptation Diseases Colorectal cancer DrugBank DB00113
FDA 1996/6/28 Pathway - UniProt -
EMA 1996/10/4
W		 Remarks In commercial reasons, marketing approval has been withdrawn in September 2005. Target Protein CEACAM
CD227
status withdraw Source http://www.ema.europa.eu/docs/en_GB/document_library/Public_statement/2009/12/WC500018313.pdf
http://www.ncbi.nlm.nih.gov/books/NBK23676/		 PDB
    Concomitant Drugs -    
- - atezolizumab TECENTRIQ PMDA - Adaptation Diseases Lung cancer DrugBank DB11595
FDA 2016/5/18 Pathway - UniProt -
EMA - Remarks In BIRCH test, which is a Phase 2 global clinical trials, it has achieved tumor reduction of non-small cell lung cancer (NSCLC) patients with locally advanced or metastatic PD-L1-positive. Correlation of PD-L1 expression amount and the antitumor effect was shown. A Phase 3 trial has been initiated Target Protein PD-L1
status approved Source http://www.roche.com/media/store/releases/med-cor-2015-08-17.htm PDB
    Concomitant Drugs -    
- - bapineuzumab - PMDA - Adaptation Diseases Alzheimer's disease DrugBank -
FDA R 2014
(phase3)		 Pathway - UniProt -
EMA - Remarks Because in both cognitive and functional outcomes also did not show a therapeutic effect in the third phase test, development has been aborted. Target Protein β-amyloid
status reject Source http://www.alzforum.org/therapeutics/bapineuzumab
http://medical.nikkeibp.co.jp/leaf/mem/pub/hotnews/nejm/201402/534930.html		 PDB
    Concomitant Drugs -    
L04AC02 L04A basiliximab
バシリキシマブ		 SIMULECT
シムレクト		 PMDA 2008/6/6 Adaptation Diseases Acute rejection after renal transplantation DrugBank DB00074
FDA 1998/5/12 Pathway Cytokine-cytokine receptor interaction, Endocytosis, Jak-STAT signaling pathway, Hematopoietic cell lineage UniProt P01589
EMA 1998/10/9 Remarks Basiliximab inhibits the function of IL-2Rα of T cells and suppress the acute rejection after renal transplantation. Target Protein CD25
status approved Source https://www.pharma.us.novartis.com/product/pi/pdf/simulect.pdf PDB 3IU3
    Concomitant Drugs -    
- - bavituximab - PMDA - Adaptation Diseases Cancer DrugBank -
FDA phase3 Pathway - UniProt -
EMA - Remarks In a randomized, double-blind, placebo-controlled study at a Phase 2 trial, good results for each adverse event was shown. A Phase 3 trial has been initiated. Target Protein phosphatidylserine
status phase III Source http://www.peregrineinc.com/clinical-trials/bavituximab-trials.html PDB
    Concomitant Drugs -    
L04AA35 L04A begelomab - PMDA - Adaptation Diseases Graft-versus-host disease DrugBank -
FDA phase3 Pathway - UniProt -
EMA - Remarks The efficary, safety and tolerability was demonstrated by pilot studies and capacity setting study. A Phase 2/3 trial has been initiated. Target Protein CD26
status phase III Source https://www.clinicaltrials.gov/ct2/show/NCT02411084 PDB
    Concomitant Drugs -    
L04AA35 L04A belatacept NULOJIX PMDA - Adaptation Diseases Rheumatoid arthritis, Graft-versus-host disease, Allograft rejection DrugBank DB06681
FDA 2011/6/15 Pathway Cell adhesion molecules (CAMs), T cell receptor signaling pathway, Rheumatoid arthritis UniProt P33681
P42081
EMA 2011/6/17 Remarks Belatacept is meinly used to treat rheumatoid arthritis, and sometimes used for a treatment of graft-versus-host disease and allograft rejection. Target Protein CD80
CD86
status approved Source http://www.medscape.com/viewarticle/744723 PDB
    Concomitant Drugs -    
L04AA28 L04A belimumab BENLYSTA PMDA - Adaptation Diseases Autoimmune disease DrugBank DB08879
FDA 2011/3/9 Pathway Cytokine-cytokine receptor interaction, Rheumatoid arthritis UniProt Q9Y275
EMA 2011/7/13 Remarks Belimumab is an autoimmune disease therapeutics. Target Protein BlyS
status approved Source http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3277870/ PDB
    Concomitant Drugs -    
L04AA26 L04A benralizumab - PMDA - Adaptation Diseases Asthma DrugBank -
FDA phase3 Pathway Cytokine-cytokine receptor interaction, Jak-STAT signaling pathway UniProt -
EMA - Remarks By comparing with placebo in a Phase 2b study, it showed that asthma exacerbation rate was decreased, and lung function and asthma control had been improved. Currently, a clinical indications for asthma and COPD severe or uncontrolled in a Phase 3 trial Target Protein IL-5R
status phase III Source https://www.astrazeneca.com/our-company/media-centre/press-releases/2014/benralizumab-study-lancet-respiratory-medicine-08092014.html PDB
    Concomitant Drugs -    
- - besilesomab SCINTIMUN PMDA - Adaptation Diseases Osteomyelitis DrugBank -
FDA - Pathway - UniProt P31997
EMA 2010/1/11 Remarks Besilesomab is a diagnostic agent. For adult patients with osteomyelitis, it used to a particular infection or inflammation area. Before using, it might be labeled with 99mTc. It can't be used in the diagnosis of diabetic foot infection. Target Protein NCA-95
status approved Source http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3070084/
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/001045/WC500075576.pdf
http://ec.europa.eu/health/documents/community-register/2010/2010011170109/anx_70109_en.pdf		 PDB
    Concomitant Drugs -    
L01XC07 L01X bevacizumab
ベバシズマブ		 AVASTIN
アバスチン		 PMDA 2007/4/18 Adaptation Diseases Colorectal cancer DrugBank DB00112
FDA 2004/2/26 Pathway Cytokine-cytokine receptor interaction, mTOR signaling pathway, VEGF signaling pathway, Pathways in cancer UniProt P15692
EMA 2005/1/12 Remarks Bevacizumab is used in the treatment of colorectal cancer, metastatic colorectal cancer, glioblastoma, metastatic and recurrent non-small cell lung cancer, relapsed primary peritoneal cancer and metastatic renal cell carcinoma. It used in combination with other anti-neoplastic agents. Target Protein VEGF
status approved Source http://www.cancer.gov/about-cancer/treatment/drugs/bevacizumab
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3227879/
http://chugai-pharm.jp/hc/ss/pr/drug/ava_via0100/pi/PDF/ava_pi.pdf		 PDB
    Concomitant Drugs 他の抗悪性腫瘍剤、（手術不能または再発乳がんの場合）paclitaxel    
J06BB21 J06B bezlotoxumab ZINPLAVA PMDA - Adaptation Diseases - DrugBank DB13140
FDA 2016/10/21 Pathway - UniProt -
EMA - Remarks ZINPLAVA reduces the recurrence of Clostridium difficile toxin B infection. Target Protein Clostridium difficile toxin B
status approved Source https://www.ncbi.nlm.nih.gov/pubmed/27905086 PDB
    Concomitant Drugs -    
- - bimagrumab - PMDA - Adaptation Diseases Muscle wasting DrugBank -
FDA phase3 Pathway - UniProt P27037
Q13705
EMA - Remarks A Phase III trial was initiated to evaluate the efficacy against muscle atrophy patients after hip fracture surgery. Target Protein activin receptor type-2A inhibitor
activin receptor type-2B inhibitor
status phase III Source http://www.fiercebiotech.com/story/novartis-win-record-breakthrough-therapy-designation-orphan-drug/2013-08-20?utm_source=rss&utm_medium=rss PDB
    Concomitant Drugs -    
L01XC19 L01X blinatumomab BLINCYTO PMDA - Adaptation Diseases Acute lymphoblastic leukaemia DrugBank DB09052
FDA 2014/12/3 Pathway T cell receptor signaling pathway, B cell receptor signaling pathway UniProt P15391
P04234
EMA 2015/11/23 Remarks Blinatumomab is used to treat acute lymphocytic leukemia. Target Protein CD19
CD3
status approved Source http://www.prnewswire.com/news-releases/amgen-announces-positive-blincyto-blinatumomab-phase-2-study-results-in-patients-with-relapsedrefractory-philadelphia-chromosome-positive-b-cell-precursor-acute-lymphoblastic-leukemia-300114629.html
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm425549.htm		 PDB
    Concomitant Drugs -    
- - bococizumab - PMDA - Adaptation Diseases Cardiovascular disorders, Hyper-cholesterolemia, Hyperlipidemia DrugBank -
FDA phase3 Pathway - UniProt -
EMA - Remarks In a Phase 2 randomized, placebo-controlled capacity setting trial, it has been shown the good results for each adverse events and serious adverse. A Phase 3 trial has been initiated in October 2013. Target Protein PCSK9
status phase III Source http://press.pfizer.com/press-release/bococizumab-rn316-significantly-reduced-ldl-cholesterol-statin-treated-adults-high-cho
http://cholestero.jugem.jp/?eid=143		 PDB
    Concomitant Drugs -    
L01XC12 L01X brentuximab vedotin
ブレンツキシマブ　ベドチン		 ADCETRIS
アドセトリス		 PMDA 2014/1/17 Adaptation Diseases Hodgkin's lymphoma, CD30-positive hematologic malignancies DrugBank DB08870
FDA 2011/8/19 Pathway - UniProt P28908
EMA 2012/10/25 Remarks Brentuximab vedotin is used for a treatment of Hodgkin's lymphoma that targets the CD30, and CD30-positive hematologic malignancies. Target Protein CD30
status approved Source http://www.seattlegenetics.com/brentuximab_vedotin PDB
    Concomitant Drugs -    
L04AC09 L04A Briakinumab - PMDA - Adaptation Diseases Crohn's disease DrugBank -
FDA phase2 Pathway - UniProt -
EMA - Remarks Briakinumab is a drug of psoriasis targeting IL-12 and IL-23-p40, which was once developed. The results of phase II and phase III studies were good, but the company withdrew the application. Target Protein -
status phase II Source http://www.ncbi.nlm.nih.gov/pubmed/25989338 PDB
    Concomitant Drugs -    
L04AC12 L04A brodalumab
ブロダルマブ		 LUMICEF
ルミセフ		 PMDA 2016/7/4 Adaptation Diseases Inflammatory disease DrugBank -
FDA - Pathway Cytokine-cytokine receptor interaction UniProt Q16552
EMA - Remarks In a phase 3 trial to make a comparison test between ustekinumab and placebo, brodalumab showed the superiority of more than ustekinumab at 12 weeks. it showed the clinical improvement of severe infection patients. Target Protein IL-17 receptor
status approved Source http://www.kyowa-kirin.co.jp/news_releases/2015/20150730_02.html
http://www.nejm.org/doi/full/10.1056/NEJMoa1503824		 PDB
    Concomitant Drugs -    
L04AC08 L04A canakinumab
カナキヌマブ		 ILARIS
イラリス		 PMDA 2011/9/26 Adaptation Diseases Muckle-wells syndrome, Rheumatoid arthritis DrugBank DB06168
FDA 2009/6/17 Pathway MAPK signaling pathway, Cytokine-cytokine receptor interaction, NOD-like receptor signaling pathway UniProt P01584
EMA 2009/10/23 Remarks Canakinumab is used for a treatment of Muckle-Wells syndrome and rheumatoid arthritis. Target Protein IL-1β
status approved Source http://healthdoctrine.com/canakinumab-novartis-drug-finds-rejection-in-us-market/
http://www.centerwatch.com/drug-information/fda-approved-drugs/drug/1263/ilaris-canakinumab		 PDB 4G5Z
4G6J
4G6K
    Concomitant Drugs -    
V09IB04 V09I capromab PROSTASCINT PMDA - Adaptation Diseases Prostate cancer DrugBank -
FDA 1996/10/28 Pathway - UniProt Q04609
EMA - Remarks Capromab is usd for a treatment of a prostate cancer Target Protein PSMA
status approved Source http://www.ncbi.nlm.nih.gov/pubmed/10850293
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080734.htm		 PDB
    Concomitant Drugs -    
L01XC09 L01X catumaxomab REMOVAB PMDA - Adaptation Diseases Cancerous ascites DrugBank -
FDA - Pathway Hematopoietic cell lineage, T cell receptor signaling pathway UniProt P16422
P09693
P07766
P04234
P20963
EMA 2009/4/20 Remarks catumaxomab is a cancerous ascites therapeutic agents. Target Protein EpCAM
CD3
status approved Source http://www.jcancer.org/v02p0309.htm PDB
    Concomitant Drugs -    
L04AB05 L04A certolizumab pegol
セルトリズマブ　ペゴル		 CIMZIA
シムジア		 PMDA 2012/12/25 Adaptation Diseases Rheumatoid arthritis, Crohn's disease DrugBank DB08904
FDA 2008/4/28 Pathway MAPK signaling pathway, Cytokine-cytokine receptor interaction, Apoptosis, TGF-beta signaling pathway, Antigen processing and presentation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Adipocytokine signaling pathway, Rheumatoid arthritis UniProt P01375
EMA 2009/10/1 Remarks Certolizumab pegol is a rheumatoid arthritis and Crohn's disease therapeutics. Combination with Abatacept is not possible. Target Protein TNFα
status approved Source http://www.prnewswire.com/news-releases/cimzia-certolizumab-pegol-approved-by-fda-for-treatment-of-adults-with-active-ankylosing-spondylitis-228312901.html PDB
    Concomitant Drugs -    
L01XC06 L01X cetuximab
セツキシマブ		 ERBITUX
アービタックス		 PMDA 2008/7/16 Adaptation Diseases Head and neck cancer, Colorectal cancer DrugBank DB00002
FDA 2004/2/12 Pathway MAPK signaling pathway, ErbB signaling pathway, Calcium signaling pathway, Cytokine-cytokine receptor interaction, Pathways in cancer UniProt P00533
EMA 2004/6/29 Remarks Cetuximab is used for a treatment of head and neck cancer, and a colon cancer. Although verification of the effect has not been made in Japan, sometimes it is used in combination with irinotecan. Target Protein EGFR
status approved Source http://www.cancer.gov/about-cancer/treatment/drugs/fda-cetuximab
http://database.japic.or.jp/pdf/newPINS/00055812.pdf#search='%E3%82%A2%E3%83%BC%E3%83%93%E3%82%BF%E3%83%83%E3%82%AF%E3%82%B9'		 PDB
    Concomitant Drugs （irinotecan）    
- - crenezumab - PMDA - Adaptation Diseases Alzheimer's disease DrugBank -
FDA phase2 Pathway - UniProt -
EMA - Remarks In a Phase 2 trial for Alzheimer's disease patients with mild to moderate, Co-primary endpoint was not met, but certain therapeutic effect was seen in mild patients. Target Protein β-amyloid
status phase II Source http://www.roche.com/investors/updates/inv-update-2014-07-16.htm
http://www.reuters.com/article/us-alzheimer-s-roche-crenezumab-idUSKBN0FL1Z820140716#xLmrP33UyIjdFEf0.97		 PDB
    Concomitant Drugs -    
L04AC01 L04A daclizumab ZENAPAX PMDA - Adaptation Diseases Asthma DrugBank DB00111
FDA 1997/12/10
W 2009		 Pathway Cytokine-cytokine receptor interaction, Endocytosis, Jak-STAT signaling pathway, Hematopoietic cell lineage UniProt P01589
P14784
EMA 1999/2/26
W		 Remarks In the past, this had been sold by Hoffman-La Roche. From commercial reasons, approval has been withdrawn in the EU in 2008, and 2009 in the United States. Target Protein CD25
status withdraw Source http://www.msdiscovery.org/research-resources/drug-pipeline PDB 3NFS
3NFP
    Concomitant Drugs -    
L04AC01 L04A daclizumab ZINBRYTA PMDA - Adaptation Diseases Relapsing-remitting MS (RRMS) DrugBank DB00111
FDA 2016/5/27 Pathway Cytokine-cytokine receptor interaction, Endocytosis, Jak-STAT signaling pathway, Hematopoietic cell lineage UniProt P01589
P14784
EMA 2016/7/1 Remarks ZINBRYTA is a remedy for relapsing-remitting MS (RRMS). It binds to the CD25 subunit of IL-2 receptor and inhibits its activity. Target Protein CD25
status approved Source https://multiplesclerosisnewstoday.com/zinbryta-for-multiple-sclerosis/ PDB 3NFS
3NFP
    Concomitant Drugs -    
L01XC24 L01X daratumumab DARZALEX PMDA - Adaptation Diseases Multiple myeloma DrugBank -
FDA 2015/11/16 Pathway Apoptosis UniProt -
EMA 2016/5/20 Remarks In July 2014, It showed that primary endpoint for Alzheimer's disease with mild to moderate in a Phase II study didn't been met. Target Protein CD38
status phase II Source http://www.roche.com/investors/updates/inv-update-2014-07-16.htm PDB
    Concomitant Drugs -    
- - demcizumab - PMDA - Adaptation Diseases Pancreatic cancer DrugBank -
FDA phase2 Pathway Notch signaling pathway UniProt Q9NR61
EMA - Remarks In a Phase 1a trial, demcizumab showed the single agent activity of the anti-tumor response. Randomized trial of a Phase 2 study has been initiated. Target Protein DLL4
status phase II Source http://www.oncomed.com/Pipeline.html PDB
    Concomitant Drugs -    
- - denosumab XGEVA PMDA - Adaptation Diseases All forms of osteoporosis or bone loss DrugBank DB06643
FDA 2010/6/1 Pathway Cytokine-cytokine receptor interaction, Osteoclast differentiation UniProt O14788
EMA 2011/7/13 Remarks It's used in order to prevent complications such as bone fractures and spinal cord compression in adults with solid tumors. Target Protein RANKL
status approved Source http://www.myelomabeacon.com/news/2009/09/22/phase-3-trial-indicates-denosumab-delays-skeletal-related-events/
http://www.myelomabeacon.com/news/2009/10/23/beacon-newsflashes-%e2%80%93-october-23-2009/
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002173/human_med_001463.jsp&mid=WC0b01ac058001d124		 PDB
    Concomitant Drugs -    
M05BX04 M05B denosumab
デノスマブ		 PROLIA
プラリア		 PMDA 2013/3/25 Adaptation Diseases Bone fracture DrugBank DB06643
FDA 2010/6/1 Pathway Cytokine-cytokine receptor interaction, Osteoclast differentiation UniProt O14788
EMA 2010/5/26 Remarks It's used in the treatment of osteoporosis to target the RANK ligand, osteoclasts. Target Protein RANKL
status approved Source http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001120/human_med_001324.jsp&mid=WC0b01ac058001d124
https://www.drugs.com/prolia.html		 PDB
    Concomitant Drugs -    
M05BX04 M05B denosumab
デノスマブ		 RANMARK
ランマーク		 PMDA 2012/1/18 Adaptation Diseases Bone lesion by multiple myeloma, Bone lesion due to solid cancer bone metastasis DrugBank DB06643
FDA - Pathway Cytokine-cytokine receptor interaction, Osteoclast differentiation UniProt O14788
EMA - Remarks RANMARK is a remedy for bone lesions due to multiple myeloma and bone lesions due to solid cancer bone metastases. Target Protein RANKL
status approved Source http://medical.nikkeibp.co.jp/leaf/all/series/drug/update/201203/523951.html PDB
    Concomitant Drugs -    
L01XC16 L01X dinutuximab UNITUXIN PMDA - Adaptation Diseases Neuroblastoma DrugBank DB09077
FDA 2015/3/10 Pathway - UniProt Q00973
EMA 2015/8/14 Remarks It's used in the treatment of neuroblastoma in children. Its target is a ganglioside GD2, which is overexpressed in malignant melanoma, neuroblastoma, osteosarcoma, and small cell lung cancer. Target Protein GD2
status approved Source http://cache.yahoofs.jp/search/cache?c=bdu7P7ovKJcJ&p=dinutuximab+phase&u=www.onclive.com%2Fweb-exclusives%2FFDA-Approves-Dinutuximab-for-High-Risk-Neuroblastoma PDB
    Concomitant Drugs -    
- - dupilumab - PMDA - Adaptation Diseases Asthma DrugBank -
FDA phase3 Pathway Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Jak-STAT signaling pathway, Hematopoietic cell lineage UniProt P24394
EMA - Remarks In a double-blind and placebo-controlled Phase 2b study for the patients with atopic dermatitis with moderate to severe, dupilumab improved the capacity dependent tumor evaluation items in any capacity. A Phase 3 trial has been initiated. Target Protein IL-4R
IL-13R
status phase III Source http://www.fiercebiotech.com/story/regeneron-speeds-toward-fda-its-would-be-asthma-blockbuster/2015-05-18
https://www.carenet.com/news/general/carenet/38386		 PDB
    Concomitant Drugs -    
- - durvalumab - PMDA - Adaptation Diseases Head and neck cancer, Non-small cell lung cancer DrugBank -
FDA phase3 Pathway - UniProt -
EMA - Remarks In a Phase 1/2 trial to evaluate the safety and tolerability, it was shown to have tolerability profile and anti-tumor activity in NCSLC. A Phase 3 trial has been initiated. Target Protein CD274
status phase III Source http://www.immunotherapyofcancer.org/content/3/S2/P193
http://www.astrazeneca.co.jp/media/pressrelease/Article/20150807		 PDB
    Concomitant Drugs -    
- - dusigitumab - PMDA - Adaptation Diseases Malignant tumor DrugBank -
FDA phase3 Pathway Proteoglycans in cancer UniProt Q6U949
EMA - Remarks A Phase III study in stage II colon cancer patient has been conducted, and the result will be compared with surgery. Target Protein IGF2
status phase III Source http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4419619/
https://clinicaltrials.gov/ct2/show/NCT00002968		 PDB
    Concomitant Drugs -    
L04AA25 L04A eculizumab
エクリズマブ		 SOLIRIS
ソリリス		 PMDA 2010/4/16 Adaptation Diseases Rheumatoid arthritis, Membranous nephritis, Lupus nephritis, Dermatomyositis, Autoimmune hemolytic anemias DrugBank DB01257
FDA 2007/3/16 Pathway Complement and coagulation cascades UniProt P01031
EMA 2007/6/20 Remarks Eculizumab is used in the treatment of rheumatoid arthritis, membranous nephritis, lupus nephritis, dermatomyositis and autoimmune hemolytic anemia. Headache,nasopharyngitis and pain of back has been confirmed as a side effect. Target Protein C5
status approved Source http://www.biospace.com/News/alexion-pharmaceuticals-inc-reports-positive/7946
 PDB
    Concomitant Drugs -    
L01XC01 L01X edrecolomab - PMDA - Adaptation Diseases Colorectal cancer DrugBank -
FDA phase3 Pathway - UniProt P16422
EMA - Remarks In a Phase 3 trials in colon cancer patients with stage II, the extension of overall survival was not observed. By integrating molecular markers and other prognostic factors, potential to ameliorate the symptoms of risk prediction was suggested. Target Protein EpCAM
status phase III Source http://jco.ascopubs.org/content/29/23/3146.abstract PDB
    Concomitant Drugs -    
L04AA21 L04A efalizumab RAPTIVA PMDA - Adaptation Diseases Transplant rejections, Pruritic DrugBank DB00095
FDA 2003/10/27 Pathway Cell adhesion molecules (CAMs), Natural killer cell mediated cytotoxicity, Leukocyte transendothelical migration, Regulation of actin cytoskeleton UniProt P20701
EMA 2004/9/20
W		 Remarks efalizumab is a CD11-targeted drug for transplant rejection and skin pruritus. Target Protein CD11
status approved Source http://www.nature.com/nrd/journal/v3/n6/full/nrd1420.html PDB 3EO9
3EOA
3EOB
3JW3
3JW5
3JVX
3JWC
3JWF
3JWK
3JWM
    Concomitant Drugs -    
- - efungumab - PMDA - Adaptation Diseases C. albicans infection DrugBank -
FDA - Pathway - UniProt -
EMA - Remarks Once efungumab had been developed for the treatment of Candida albicans infections. Target Protein fungal HSP90
status reject Source http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000658/WC500070523.pdf PDB
    Concomitant Drugs -    
L01XC23 L01X elotuzumab
エロツズマブ		 EMPLICITI
エムプリシティ		 PMDA 2016/9/28 Adaptation Diseases Cancer DrugBank -
FDA 2015/11/30 Pathway - UniProt Q9NQ25
EMA 2016/5/11 Remarks Elotuzumab is used for the treatment of multiple myeloma. It's used in combination with lenalidomide and dexamethasone. Target Protein SLAMF7
status approved Source http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm474719.htm
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm474684.htm
https://myeloma.gr.jp/userfiles/file/medical_info/ID340_J.pdf
http://www.who.int/medicines/publications/druginformation/issues/WHO_DI_29-4_ATC-DDD.pdf		 PDB
    Concomitant Drugs -    
- - epratuzumab - PMDA - Adaptation Diseases Acute lymphoblastic leukaemia, Systemic lupus erythematosus DrugBank -
FDA phase3 Pathway - UniProt -
EMA - Remarks In a randomized, double-blind and placebo control Phase 3, no advantage is seen for placebo. Trial of systemic lupus erythematosus is being continued. Target Protein CD19
CD22
Reactive oxygen species
status phase III Source http://www.ucb.com/presscenter/News/article/UCB-announces-Phase-3-clinical-trial-program-for-epratuzumab-in-Systemic-Lupus-Erythematosus-did-not-meet-primary-endpoint-nbsp PDB
    Concomitant Drugs -    
L04AB01 L04A etanercept BENEPALI PMDA - Adaptation Diseases Moderate to severe rheumatoid arthritis, Psoriatic arthritis, Non-radiographic axial spondyloarthritis, Plaque psoriasis DrugBank DB00005
FDA - Pathway - UniProt P01375
EMA 2016/1/14 Remarks BENEPALI is a biosimulator of ENBREL. It’s used for the treatment of moderate to severe rheumatoid arthritis, psoriatic arthritis, nonradiolative spondyloarthritis and plaque psoriasis in adults. Target Protein TNFα
TNFβ
status approved Source http://www.businesswire.com/news/home/20160116005011/en/BENEPALI%c2%ae-Etanercept-Biosimilar-Referencing-Enbrel%c2%ae-Approved-European PDB
    Concomitant Drugs -    
L04AB01 L04A etanercept
エタネルセプト		 ENBREL PMDA 2005/1/19 Adaptation Diseases Moderate to severe rheumatoid arthritis, Polyarticular juvenile idiopathic arthritis, Psoriatic arthritis, Ankylosing spondylitis DrugBank DB00005
FDA 1998/11/2 Pathway - UniProt P01375
EMA 2000/2/3 Remarks Etanercept is a TNF-α-targeted drug for rheumatoid arthritis and plaque psoriasis with moderate to severe. Although not required, it's also be used in conjunction with Rheumatrex. Combination with abatacept is not possible. Target Protein TNFα
TNFβ
status approved Source http://www.ncbi.nlm.nih.gov/pubmed/11816834
http://www.skintherapyletter.com/2006/11.1/1.html
http://www.rheuma-net.or.jp/rheuma/rm400/rm400_chiryo_seibutsugakutekiseizai.html		 PDB
    Concomitant Drugs （Rheumatrex）    
L04AB01 L04A etanercept-szzs ERELZI PMDA - Adaptation Diseases Moderate to severe rheumatoid arthritis, Polyarticular juvenile idiopathic arthritis, Psoriatic arthritis, Ankylosing spondylitis, Plaque psoriasis DrugBank DB00005
FDA 2016/8/30 Pathway - UniProt P01375
EMA - Remarks ERELZI is a biosimulator of ENBREL. It's used for moderate to severe rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis. Target Protein TNFα
TNFβ
status approved Source http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm518639.htm PDB
    Concomitant Drugs -    
- - etaracizumab - PMDA - Adaptation Diseases Metastatic melanoma, Prostate cancer DrugBank -
FDA R 2007
(phase2)		 Pathway Focal adhesion, ECM-receptor interaction, Regulation of actin cytoskeleton UniProt P05106
P06756
EMA - Remarks A Phase 2 randomized, open-label, in the second group of dacarbazine and etaracizumab study for metastatic melanoma patients, was performed to verify the safety and anti-tumor effect. As a result, a large difference in symptom improvement in the dacarbazine + etaracizumab group and etaracizumab group did not appear. Target Protein integrein αVβ3
status reject Source http://onlinelibrary.wiley.com/doi/10.1002/cncr.24821/full PDB
    Concomitant Drugs -    
- - etrolizumab - PMDA - Adaptation Diseases Inflammatory bowel disease DrugBank -
FDA phase3 Pathway Focal adhesion, ECM-receptor interaction, Cell adhesion molecules (CAMs) UniProt P13612
P26010
P38570
EMA - Remarks As a result of a double-blind placebo-controlled and randomized Phase II study for the patient of ulcerative colitis, etrolizumab's symptom improvement was faster than that of placebo for 10 weeks. A Phase 3 trial has been initiated. Target Protein integrein α4β7
integrein αEβ7
status phase III Source http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)60661-9/abstract PDB
    Concomitant Drugs -    
C10AX13 C10A evolocumab
エボロクマブ		 REPATHA
レパーサ		 PMDA 2016/1/22 Adaptation Diseases Hyperlipidemia DrugBank -
FDA 2015/8/27 Pathway - UniProt Q8NBP7
EMA 2015/7/17 Remarks Evolocumab is a PCSK9 target drugs used for the treatment of familial hypercholesterolemia. Target Protein PCSK9 inhibitor
status approved Source http://www.sciencedirect.com/science/article/pii/S0735109714017276
http://www.medscape.com/viewarticle/848370
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm460082.htm		 PDB
    Concomitant Drugs -    
- - fresolimumab - PMDA - Adaptation Diseases Malignant melanoma, Pulmonary fibrosis, Renal cancer DrugBank -
FDA phase2 Pathway - UniProt -
EMA - Remarks In an open-label, dose finding and pharmacokinetic evaluation of a single dose injection Phase 1 trial for the primary resistance FSGS patients , good results were obtained. A Phase 2 trial has been initiated. Target Protein TGFβ
status phase II Source http://www.ncbi.nlm.nih.gov/pubmed/21368745 PDB
    Concomitant Drugs -    
- - gantenerumab - PMDA - Adaptation Diseases Alzheimer's disease DrugBank -
FDA R 2014
(phase3)		 Pathway - UniProt P05067
EMA - Remarks A Phase 2/3 trial is the trial of CDRs-SOB and cerebral amyloid levels change for patients with early symptoms of Alzheimer's disease, and good results were obtained. A Phase 3 trial had been continued from March 2014, but new safety signals were not observed. The trial was discontinued in December 2014. Target Protein β-amyloid
status reject Source http://www.chugai-pharm.co.jp/news/detail/20141219150001.html
http://www.roche.com/media/store/releases/med-cor-2014-12-19b.htm		 PDB
    Concomitant Drugs -    
L01XC05 L01X gemtuzumab ozogamicin
ゲムツズマブオゾガマイシン		 MYLOTARG
マイロターグ		 PMDA 2005/7/25 Adaptation Diseases Relapsed and acute myelogenous leukemia DrugBank DB00056
FDA 2000/5/17
W 2010/6/21		 Pathway Hematopoietic cell lineage UniProt P20138
EMA R Remarks In the interim analysis of post-marketing randomized phase 3 trial in the United States started in 2004, it was found that there are many deaths in the gemtuzumab combination group. In addition, the incidence of hepatic veno-occlusive disease in gemtuzumab combination group, was higher than the value at the time of approval. In the United States, the test was canceled in 2009, and sale canceled in 2010. Combination with other anti-neoplastic agents have not been thoroughly tested. Target Protein CD33
status approved Source http://medical.nikkeibp.co.jp/leaf/all/search/cancer/news/201006/515734.html
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm216458.htm		 PDB
    Concomitant Drugs -    
- - gevokizumab - PMDA - Adaptation Diseases Diabetes, Inflammatory disorders DrugBank -
FDA phase3 Pathway MAPK signaling pathway, Cytokine-cytokine receptor interaction, NOD-like receptor signaling pathway UniProt P01584
EMA - Remarks Currently, double-blind, a third-phase trial of placebo controls have been implemented to pyoderma gangrenosum patients. Target Protein IL-1β
status phase III Source http://www.xoma.com/content/pipeline/gevokizumab.htm PDB
    Concomitant Drugs -    
- - girentuximab - PMDA - Adaptation Diseases Suspended Renal cancer DrugBank -
FDA phase2 Pathway - UniProt -
EMA - Remarks A Phase II study, to evaluate the safety and efficacy in renal cell cancer for refractory metastatic renal cell cancer patients, has been initiated. Target Protein CAIX
status phase II Source https://clinicaltrials.gov/show/NCT01253668 PDB
    Concomitant Drugs -    
L04AB06 L04A golimumab SIMPONI ARIA PMDA - Adaptation Diseases Rheumatoid arthritis DrugBank DB06674
FDA 2013/7/18 Pathway MAPK signaling pathway, Cytokine-cytokine receptor interaction, TGF-beta signaling pathway, Fc epsilon RI signaling pathway, Adipocytokine signaling pathway, Asthma, Rheumatoid arthritis UniProt P01375
EMA - Remarks SIMPONI ARIA, an intravenous injection type of SIMPONI, is used as a remedy for rheumatoid arthritis. Target Protein TNFα
status approved Source https://www.drugs.com/pro/simponi-aria.html
http://www.webmd.com/drugs/2/drug-164798/simponi-aria-intravenous/details		 PDB
    Concomitant Drugs -    
L04AB06 L04A golimumab
ゴリムマブ		 SIMPONI
シンポニー		 PMDA 2011/7/1 Adaptation Diseases Inflammatory disorders, Rheumatoid arthritis, Uveitis, asthma, Crohn's disease DrugBank DB06674
FDA 2009/4/24 Pathway MAPK signaling pathway, Cytokine-cytokine receptor interaction, TGF-beta signaling pathway, Fc epsilon RI signaling pathway, Adipocytokine signaling pathway, Asthma, Rheumatoid arthritis UniProt P01375
EMA 2009/10/1 Remarks Golimumab is used in the treatment of inflammatory disease, rheumatoid arthritis, uveitis, asthma and Crohn's disease. Combination with abatacept is not possible. Target Protein TNFα
status approved Source http://www.ccfa.org/news/simponi.html PDB
    Concomitant Drugs -    
- - GSK2398852 - PMDA - Adaptation Diseases Amyloidosis DrugBank -
FDA phase2 Pathway - UniProt -
EMA - Remarks GSK2398852 is used to the treatment of amyloidosis that is a specific disease. Target Protein Serum amyloid P
status phase II Source http://www.gsk-clinicalstudyregister.com/study/115570#ps
http://www.gsk-clinicalstudyregister.com/study/115970#ps
http://www.bcshguidelines.com/documents/Amyloid_2014.pdf		 PDB
    Concomitant Drugs -    
- - guselkumab - PMDA - Adaptation Diseases Inflammatory diseases, Psoriasis DrugBank -
FDA phase3 Pathway - UniProt P35225
EMA - Remarks In a randomized, placebo-controlled study at a Phase 2b trial, it met the PGA score at 16 weeks. A Phase 3 trial has been initiated. Target Protein IL-13 subunit p19
status phase III Source http://www.investor.jnj.com/releaseDetail.cfm?releaseid=835041 PDB
    Concomitant Drugs -    
V10XX02 V10X ibritumomab tiuxetan
イットリウム（90Y）イブリツモマブ　チウキセタン
インジウム（111In）イブリツモマブ　チウキセタン		 ZEVALIN
ゼヴァリン		 PMDA 2008/1/25 Adaptation Diseases Metastatic melanoma DrugBank DB00078
FDA 2002/2/19 Pathway Hematopoietic cell lineage UniProt P11836
EMA 2004/1/16 Remarks Ibritumomab tiuxetan is the drug of metastatic melanoma by binding to CD20 of B cells. There are side effects such as nausea, vomiting, diarrhea anorexia and more. Target Protein CD20
status approved Source http://www.centerwatch.com/drug-information/fda-approved-drugs/drug/762/zevalin-ibritumomab-tiuxetan PDB
    Concomitant Drugs -    
V03AB37 V03A idarucizumab
イダルシズマブ		 PRAXBIND
プリズバインド		 PMDA 2016/9/28 Adaptation Diseases Blood coagulation disorders DrugBank DB09264
FDA 2015/10/16 Pathway - UniProt P11836
EMA 2015/11/20 Remarks Idarucizumab is used for the treatment of blood coagulation disorders. Target Protein -
status approved Source https://www.boehringer-ingelheim.com/news/news_releases/press_releases/2015/19_october_2015_dabigatranetexilate.html PDB
    Concomitant Drugs -    
- - igovomab Indimacis 125 PMDA - Adaptation Diseases Ovarian cancer DrugBank -
FDA - Pathway - UniProt -
EMA 1996/10/4
W		 Remarks Once it was used in the treatment of ovarian cancer. Target Protein -
status withdraw Source http://biopharma.fmsdb.com/full7.lasso?order=302&site=Fox&DB_test=&S=&-token=none&-nothing
http://medical.nikkeibp.co.jp/leaf/all/search/cancer/news/201006/515734.html		 PDB
    Concomitant Drugs -    
V09GX02 V09G imciromab pentetate MYOSCINT PMDA - Adaptation Diseases (Cardiac imaging) DrugBank -
FDA 1996/7/3
W		 Pathway - UniProt -
EMA - Remarks MYOSCINT was once used to image the heart. It binds to the myosin heavy chain present in cardiomyocytes and skeletal muscle cells. Target Protein Myosin
status withdraw Source http://www.accessdata.fda.gov/drugsatfda_docs/label/1996/imcicen070396-lab.pdf
https://www.pharmacodia.com/yaodu/html/v1/biologics/b7046757c3682a28c5bf2024e57678a0.html		 PDB
    Concomitant Drugs -    
L04AB02 L04A infliximab FLIXABI PMDA - Adaptation Diseases Rheumatoid arthritis, Crohn’s disease, Ulcerative colitis, Ankylosing spondylitis, Psoriatic arthritis, Psoriasis DrugBank DB00065
FDA - Pathway MAPK signaling pathway, Cytokine-cytokine receptor interaction, Apoptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Adipocytokine signaling pathway, Rheumatoid arthritis UniProt P01375
EMA 2016/5/26 Remarks FLIXABI is a biosimilar of Remicade which is used as an anti-inflammatory drug in the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, psoriasis. It’s used in combination with Methotrexate (MTX). Target Protein TNFα
status approved Source http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004020/human_med_001980.jsp&mid=WC0b01ac058001d124 PDB 4G3Y
3WD5
    Concomitant Drugs Methotrexate    
L04AB02 L04A infliximab REMSIMA PMDA - Adaptation Diseases Rheumatoid arthritis, Crohn’s disease, Ulcerative colitis, Ankylosing spondylitis, Psoriatic arthritis, Psoriasis DrugBank DB00065
FDA - Pathway MAPK signaling pathway, Cytokine-cytokine receptor interaction, Apoptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Adipocytokine signaling pathway, Rheumatoid arthritis UniProt P01375
EMA 2013/9/10 Remarks REMSIMA is a biosimilar of Remicade which is used as an anti-inflammatory drug in the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, psoriasis. It’s used in combination with Methotrexate (MTX). Target Protein TNFα
status approved Source http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002576/human_med_001682.jsp&mid=WC0b01ac058001d124 PDB 4G3Y
3WD5
    Concomitant Drugs Methotrexate    
L04AB02 L04A infliximab
インフリキシマブ		 REMICADE
レミケード		 PMDA 2002/1/17 Adaptation Diseases Rheumatoid arthritis, Crohn’s disease, Ulcerative colitis, Ankylosing spondylitis, Psoriatic arthritis, Psoriasis DrugBank DB00065
FDA 1998/8/24 Pathway MAPK signaling pathway, Cytokine-cytokine receptor interaction, Apoptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Adipocytokine signaling pathway, Rheumatoid arthritis UniProt P01375
EMA 1999/8/13 Remarks REMICADE is used for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, psoriasis. It’s used in conjunction with Rheumatrex. Target Protein TNFα
status approved Source http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727775/
http://www.aetna.com/cpb/medical/data/300_399/0341.html
http://www.rheuma-net.or.jp/rheuma/rm400/rm400_chiryo_seibutsugakutekiseizai.html
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000240/human_med_001023.jsp&mid=WC0b01ac058001d124		 PDB 4G3Y
3WD5
    Concomitant Drugs Rheumatrex    
L04AB02 L04A infliximab-dyyb
インフリキシマブ		 INFLECTRA
インフレクトラ		 PMDA 2014/7/4 Adaptation Diseases Rheumatoid arthritis, Crohn’s disease, Ulcerative colitis, Ankylosing spondylitis, Psoriatic arthritis, Psoriasis DrugBank DB00065
FDA 2016/4/5 Pathway MAPK signaling pathway, Cytokine-cytokine receptor interaction, Apoptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Adipocytokine signaling pathway, Rheumatoid arthritis UniProt P01375
EMA 2013/9/10 Remarks INFLECTRA is a biosimilar of Remicade which is used as an anti-inflammatory drug in the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, psoriasis. It’s used in combination with Methotrexate (MTX). Target Protein TNFα
status approved Source http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002778/human_med_001677.jsp&mid=WC0b01ac058001d124 PDB
    Concomitant Drugs Methotrexate    
L01XC26 L01X inotuzumab ozogamicin - PMDA - Adaptation Diseases Metastatic melanoma DrugBank -
FDA R 2013
(phase3)		 Pathway Cell adhesion molecules (CAMs), B cell receptor signaling pathway UniProt P11836
EMA - Remarks Randomized composed of two groups to evaluate the safety and efficacy and open-label at a Phase 3 trial had been perfomed, but the superiority against combination therapy with rituximab was not seen. Incidentally, new or unexpected safety issues were identified. Upon receiving the result, third-phase trial was stopped in May 2013. Target Protein CD20
status reject Source http://press.pfizer.com/press-release/pfizer-discontinues-phase-3-study-inotuzumab-ozogamicin-relapsed-or-refractory-aggress PDB
    Concomitant Drugs -    
L01XC11 L01X ipilimumab
イピリムマブ		 YERVOY
ヤーボイ		 PMDA 2015/7/3 Adaptation Diseases Oncology disease and HIV infection, Malignant melanoma DrugBank DB06186
FDA 2011/3/25 Pathway Cell adhesion molecules (CAMs), B cell receptor signaling pathway UniProt P16410
EMA 2011/7/13 Remarks Ipilimumab is used in the treatment of tumor diseases and malignant melanoma. It's also used in the treatment of HIV-infected persons. It's used in combination with bevacizumab or vemurafenib. Target Protein CTLA4
status approved Source http://www.aetna.com/cpb/medical/data/800_899/0815.html PDB
    Concomitant Drugs bevacizumabもしくはvemurafenib    
L04AC13 L04A ixekizumab
イキセキズマブ		 TALTZ
トルツ		 PMDA 2016/7/4 Adaptation Diseases Plaque psoriasis, Psoriatic arthritis, Rheumatoid arthritis DrugBank DB11569
FDA 2016/3/22 Pathway - UniProt Q16552
EMA 2016/4/25 Remarks TALTZ is a remedy for arthropathic psoriasis, rheumatoid arthritis, rigidity myelitis. Target Protein IL-17
status approved Source http://www.nejm.org/doi/full/10.1056/NEJMoa1109997
https://www.lilly.co.jp/pressrelease/2012/news_2012_101.aspx		 PDB
    Concomitant Drugs -    
- - labetuzumab - PMDA - Adaptation Diseases Colorectal cancer DrugBank -
FDA phase2 Pathway - UniProt P06731
EMA - Remarks In a Phase 2 study, to examine the radioimmunotherapy after salvage resection of liver metastases (LM), improvement in symptoms was observed. From now on, it's expected to make a further assessment of a randomized trial. Target Protein CEA
status phase II Source http://jco.ascopubs.org/content/23/27/6763.full.pdf PDB
    Concomitant Drugs -    
- - lampalizumab - PMDA - Adaptation Diseases Age-related macular degeneration DrugBank -
FDA phase3 Pathway - UniProt -
EMA - Remarks On a Placebo-controlled phase 2 trial, it showed that in the group of Geographic atrophy (GA) patients who were administered once a month lampalizumab, the GA progression rate after 18 months was reduced by 44%. Receiving this result, a Phase 3 trial against GA and age-related macular degeneration (AMD) disease has been initiated from September 2014. Target Protein CFD
status phase III Source http://www.roche.com/investors/updates/inv-update-2013-08-27.htm
http://www.roche.com/investors/updates/inv-update-2014-09-15.htm		 PDB
    Concomitant Drugs -    
- - lebrikizumab - PMDA - Adaptation Diseases Asthma DrugBank -
FDA phase3 Pathway Cytokine-cytokine receptor interaction, Jak-STAT signaling pathway, Asthma UniProt P35225
EMA - Remarks A Phase 2 trial had been carried out for asthma patients inhaled corticosteroids did not work. As a result, high periostin concentration patient group was reduced 60% while low group was reduced 5%. In the high periostin concentration group patients, it showed that the lung function was improved by the increase in volume in one second. a Phase 3 trial has been initiated. Target Protein IL-13
status phase III Source http://www.roche.com/media/store/releases/med-cor-2014-03-05.htm
http://www.chugai-pharm.co.jp/news/detail/20140305150200.html		 PDB
    Concomitant Drugs -    
- - lifastuzumab vedotin - PMDA - Adaptation Diseases Ovarian cancer DrugBank -
FDA phase2 Pathway - UniProt -
EMA - Remarks Because of a good result of a Phase 1 trial for patient non-small cell lung cancer and ovarian cancer, a Phase 2 trial for patient platinum-resistant ovarian cancer has been initiated. Target Protein NaPi2b
status phase II Source http://adcreview.com/tag/lifastuzumab-vedotin/
http://adcreview.com/lifastuzumab-vedotin-clinical-trials/		 PDB
    Concomitant Drugs -    
- - lintuzumab - PMDA - Adaptation Diseases Acute myeloid leukaemia, Myelodysplastic syndromes DrugBank -
FDA R 2010
(phase2b)		 Pathway - UniProt -
EMA - Remarks A Phase 2b study for acute myeloid leukemia (AML) in elderly patients had been carried out. However, it was shown that it did not meet the lifetime extension of the primary endpoint. Receiving the result, the development was discontinued in September 2010. Target Protein CD33
status reject Source http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=1470001 PDB
    Concomitant Drugs -    
- - lorvotuzumab mertansine - PMDA - Adaptation Diseases Haematological malignancies, Multiple myeloma DrugBank -
FDA phase2 Pathway Cell adhesion molecules (CAMs) UniProt P13591
EMA - Remarks As a result of aPhase I trial for patient relapsed and refractory myeloma, it showed that it can be effectively treated in combination with existing drugs Revlimid. A Phase 2 trial has been initiated. Target Protein CD56
status phase II Source http://adcreview.com/tag/lifastuzumab-vedotin/
http://www.myelomabeacon.com/news/2013/01/04/lorvotuzumab-mertansine-combination-in-relapsed-refractory-multiple-myeloma-patients-ash-2012/
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3984343/		 PDB
    Concomitant Drugs -    
- - lulizumab pegol - PMDA - Adaptation Diseases Systemic lupus erythematosus DrugBank -
FDA phase2 Pathway - UniProt -
EMA - Remarks Currently, a multicenter, randomized, double-blind and placebo-controlled Phase 2 trial for patients with systemic lupus erythematosus has been carried out. The result will evaluate the safety and efficacy. Target Protein CD28
status phase II Source http://www.ncbi.nlm.nih.gov/pubmed/22801961
http://www.news-medical.net/news/20100913/Seattle-Genetics-lintuzumab-phase-IIb-clinical-trial-for-AML-does-not-meet-primary-endpoint.aspx
http://cc.bingj.com/cache.aspx?q=lulizumab+phase&d=4558782892409274&mkt=ja-JP&setlang=ja-JP&w=D76AvIKR9wQZGAwHFV8iLcRRb9hLFdLx		 PDB
    Concomitant Drugs -    
- - margetuximab - PMDA - Adaptation Diseases Breast cancer DrugBank -
FDA phase2 Pathway - UniProt -
EMA - Remarks Margetuximab is a drug under development for breast cancer. A phase IIa study has been carried out on people with low HER2 expression or patients with refractory breast cancer. A phase III study will be start on the end of 2015. Target Protein ERBB2
status phase II Source http://www.macrogenics.com/products-margetuximab.html PDB
    Concomitant Drugs -    
- - mavrilimumab - PMDA - Adaptation Diseases Rheumatoid arthritis DrugBank -
FDA phase2 Pathway Cytokine-cytokine receptor interaction, Jak-STAT signaling pathway UniProt P15509
EMA - Remarks Currently, a Phase 2a study for the people whose HER2 expression was low and refractory breast cancer patients, has been carried out. From the end of 2015, it is expected to start a Phase 3 trial. Target Protein CD116
status phase II Source http://www.ncbi.nlm.nih.gov/pubmed/23234647 PDB
    Concomitant Drugs -    
R03DX09 R03D mepolizumab
メポリズマブ		 NUCALA
ヌーカラ		 PMDA 2016/3/28 Adaptation Diseases Asthma DrugBank -
FDA 2015/11/4 Pathway Cytokine-cytokine receptor interaction, Jak-STAT signaling pathway UniProt P05113
EMA 2015/12/2 Remarks As a result of double-blind, placebo-controlled phase 2 trial for patients rheumatoid arthritis, Rapid clinical response was observed. It is expected to authenticate as a new drug that inhibits mononuclear phagocyte pathway. Target Protein IL-5
status approved Source http://www.lse.co.uk/AllNews.asp?code=miw3m7gx PDB
    Concomitant Drugs -    
- - milatuzumab - PMDA - Adaptation Diseases Multiple myeloma, Other hematological malignancies DrugBank -
FDA phase2 Pathway Antigen processing and presentation UniProt P04233
EMA - Remarks As a result of a Phase 1 trial for patients with recurrent non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL), good results were obtained. A Phase 1/2 study of veltuzumab combination for recurrent multiple myeloma patient has been initiated. Target Protein CD74
status phase II Source http://www.immunomedics.com/milatuzumab.shtml PDB
    Concomitant Drugs -    
- - mitumomab - PMDA - Adaptation Diseases Malignant melanoma, Small cell lung cancer DrugBank -
FDA R 2005
(phase3)		 Pathway - UniProt Q92185
EMA - Remarks Mitumomab had been developed as a medicine for malignant melanoma and small cell lung cancer once. Target Protein GD3
status reject Source http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3126006/ PDB
    Concomitant Drugs -    
L01XC25 L01X mogamulizumab
モガムリズマブ		 POTELIGEO
ポテリジオ		 PMDA 2012/3/30 Adaptation Diseases PTCL, CTCL DrugBank -
FDA - Pathway Cytokine-cytokine receptor interaction, Chemokine signaling pathway UniProt P51679
EMA - Remarks Mogamulizumab is used in the treatment of peripheral T cell lymphoma and cutaneous T-cell lymphoma. There are side effects of the blood toxicity such as lymphocyte count, leukopenia and neutropenia number, and the non-hematological toxicity such as fever, skin disorders (rash, etc.), acute infusion reaction platelet. When using this, it administered in combination with VCAP, AMP, the VECP. Target Protein CCR4
status approved Source http://www.kyowa-kirin.co.jp/news_releases/2012/20121211_01.html
http://www.kyowa-kirin.co.jp/news_releases/2012/20120529_02.html
http://www.ncbi.nlm.nih.gov/pubmed/25605368
http://jco.ascopubs.org/content/early/2014/03/10/JCO.2013.52.0924
http://www.who.int/medicines/publications/druginformation/issues/WHO_DI_29-4_ATC-DDD.pdf
http://www.e-pharma.jp/druginfo/tempbunsyo/4291422A1021		 PDB
    Concomitant Drugs VCAP（ビンクリスチン硫酸塩、シクロホスファミド水和物、ドキソルビシン塩酸塩、プレドニゾロン）、AMP（ドキソルビシン塩酸塩、ラニムスチン、プレドニゾロン）、VECP（ビンデシン硫酸塩、エトポシド、カルボプラチン、プレドニゾロン）    
J06BB17 J06B motavizumab - PMDA - Adaptation Diseases - DrugBank -
FDA R 2013
(phase3)		 Pathway - UniProt -
EMA - Remarks - Target Protein RSV
status reject Source http://www.drugs.com/history/motavizumab.html PDB
    Concomitant Drugs -    
- - moxetumomab pasudotox - PMDA - Adaptation Diseases Cancer DrugBank -
FDA phase3 Pathway Cell adhesion molecules (CAMs), B cell receptor signaling pathway UniProt P20273
EMA - Remarks As a result of a Phase 1 trial for relapsed or refractory hairy cell leukemia (HCL) patient, it achieved as same response speed as that without dose-limiting toxicity. A Phase 3 trial has been initiated. Target Protein CD22
status phase III Source https://clinicaltrials.gov/ct2/show/NCT01829711
http://www.ncbi.nlm.nih.gov/pubmed/22003067		 PDB
    Concomitant Drugs -    
- - muromonab-CD3 ORTHOCLONE OKT3 PMDA - Adaptation Diseases Organ rejection after a kidney transplant DrugBank DB00075
FDA 1992/9/14 Pathway T cell receptor signaling pathway UniProt P04234
P07766
P09693
P20963
EMA - Remarks Muromonab-CD3 is used to prevent organ rejection after renal transplantation. Target Protein CD3
status approved Source http://www.ncbi.nlm.nih.gov/pubmed/16862164
http://onlinelibrary.wiley.com/doi/10.1002/9783527682423.ch60/summary		 PDB
    Concomitant Drugs -    
- - natalizumab NATALIZUMAB ELAN PHARMA PMDA - Adaptation Diseases - DrugBank -
FDA - Pathway - UniProt -
EMA R Remarks - Target Protein -
status reject Source - PDB
    Concomitant Drugs -    
L04AA23 L04A natalizumab
ナタリズマブ		 TYSABRI
タイサブリ		 PMDA 2014/3/24 Adaptation Diseases PML DrugBank DB00108
FDA 2004/11/23 Pathway Focal adhesion, ECM-receptor interaction, Cell adhesion molecules (CAMs), Leukocyte transendothelical migration UniProt P13612
EMA 2006/6/27 Remarks Natalizumab is used for the treatment of progressive multifocal leukoencephalopathy (PML). There are side effects of encephalitis, meningitis, liver injury, severe allergic reaction, and weakening of the immune system. Target Protein integrin α4
status approved Source http://www.medscape.com/viewarticle/782319_2
http://www.fda.gov/downloads/Drugs/Drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm288126.pdf		 PDB 4IRZ
    Concomitant Drugs -    
J06BC01 J06B necitumumab PORTRAZZA PMDA - Adaptation Diseases Non-small cell lung cancer DrugBank -
FDA 2015/11/24 Pathway - UniProt -
EMA 2016/2/15 Remarks As a result of a Phase 3 SQUIRE trial, combination to gemcitabine + cisplatin for patients with advanced squamous non-small cell lung cancer Stage IV, there was a statistically significant improvement in overall survival. Target Protein EGFR
status approved Source https://www.lilly.co.jp/pressrelease/2014/news_2014_012.aspx PDB
    Concomitant Drugs -    
L01XC22 L01X necitumumab - PMDA - Adaptation Diseases - DrugBank -
FDA phase3 Pathway - UniProt -
EMA - Remarks Necitumumab is a drug that inhibits the binding of EGFR1 and a ligand, thereby inhibiting disease progression, induction of angiogenesis and apoptosis or cancer cell death. in a phase III study, good results were obtained. Target Protein -
status phase III Source - PDB
    Concomitant Drugs -    
- - nesvacumab - PMDA - Adaptation Diseases Cancer DrugBank -
FDA R 2014
(phase1)		 Pathway HIF-1 signaling pathway, PI3K-Akt signaling pathway UniProt -
EMA - Remarks Nesvacumab had been developed as an anti-cancer agent once. Target Protein ANG2
status reject Source https://clinicaltrials.gov/ct2/show/NCT01271972
https://clinicaltrials.gov/ct2/show/NCT01688960		 PDB
    Concomitant Drugs -    
- - nimotuzumab THERALOC PMDA phase3 Adaptation Diseases Glioblastoma, Glioma, Head and neck cancer, Nasopharyngeal cancer DrugBank -
FDA 2015 Pathway - UniProt -
EMA - Remarks Nimotuzumab is used in the treatment of glioblastoma, glioma, head and neck cancer and nasopharyngeal carcinoma. Target Protein EGFR
status approved Source http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427716.htm
http://www.pharmacodia.com/web/drug/1_722.html		 PDB
    Concomitant Drugs -    
L01XC17 L01X nivolumab NIVOLUMAB BMS PMDA - Adaptation Diseases - DrugBank -
FDA - Pathway - UniProt -
EMA 2015/7/20
W		 Remarks - Target Protein -
status withdraw Source - PDB
    Concomitant Drugs -    
L01XC17 L01X nivolumab
ニボルマブ		 OPDIVO
オプジーボ		 PMDA 2014/7/4 Adaptation Diseases Melanoma DrugBank DB09035
FDA 2015/3/4 Pathway - UniProt Q15116
EMA 2015/6/19 Remarks Nivolimab is used in the treatment of unresectable or metastatic melanoma. There are side effects of Rash, itching, cough, upper respiratory tract infection and fluid retention. Target Protein PD-1
status approved Source http://blog.aacr.org/fda-approval-nivolumab/ PDB
    Concomitant Drugs -    
- - nofetumomab VERLUMA PMDA - Adaptation Diseases Diagnosis of Lung cancer, Gastrointestinal, breast, Ovary, Pancreas, Kidney, Cervix, Bladder carcinoma DrugBank -
FDA 1996/8/20 Pathway - UniProt -
EMA - Remarks VERLUMA is a mouse monoclonal antibody used for cancer diagnosis. Target Protein human MS4A1
status approved Source http://www.creative-biolabs.com/Anti-MS4A1%20Therapeutic%20Antibody%20(VERLUMA)_604_6.htm PDB
    Concomitant Drugs -    
- - obiltoxaximab ANTHIM PMDA - Adaptation Diseases Inhalational anthrax due to Bacillus anthracis DrugBank -
FDA 2016/3/18 Pathway - UniProt -
EMA - Remarks ANTHIM is a remedy used for treatment of inhalation anthrax by anthrax. Target Protein CD20
status approved Source http://www.anthim.com/ PDB
    Concomitant Drugs -    
L01XC15 L01X obinutuzumab GAZYVA (GAZYVARO) PMDA - Adaptation Diseases Multiple sclerosis, Lymphoma DrugBank DB08935
FDA 2013/11/1 Pathway Hematopoietic cell lineage UniProt P11836
EMA 2014/7/23 Remarks Obinutuzumab is used in the treatment of multiple sclerosis and lymphoma. Target Protein CD20
status approved Source http://www.gene.com/media/press-releases/14487/2013-07-02/fda-grants-genentechs-obinutuzumab-ga101 PDB
    Concomitant Drugs -    
L04AA36 L04A ocrelizumab - PMDA - Adaptation Diseases Rheumatoid arthritis DrugBank -
FDA R 2010
(phase3)		 Pathway Hematopoietic cell lineage UniProt P11836
EMA - Remarks As a result of a Phase 3 study, there were no overall benefit in terms of safety and efficacy. Development has been aborted. Target Protein CD20
status reject Source http://www.roche.com/investors/updates/inv-update-2010-05-19.htm PDB
    Concomitant Drugs -    
L01XC10 L01X ofatumumab
オファツムマブ		 ARZERRA
アーゼラ		 PMDA 2013/3/25 Adaptation Diseases Chronic lymphocytic leukemia DrugBank -
FDA 2009/10/26 Pathway Hematopoietic cell lineage UniProt P11836
EMA 2010/4/19 Remarks Ofatumumab is a treatment of chronic lymphocytic leukemia, targeting the CD20 on the B cell surface. Target Protein CD20
status approved Source http://globenewswire.com/news-release/2015/11/23/789750/0/en/Genmab-Announces-Ofatumumab-Phase-III-Study-in-Follicular-Lymphoma-to-be-Stopped-Following-Planned-Interim-Analysis.html
http://www.cancer.gov/about-cancer/treatment/drugs/fda-ofatumumab		 PDB 3GIZ
    Concomitant Drugs -    
- - olaratumab LARTRUVO PMDA - Adaptation Diseases Soft Tissue Sarcoma DrugBank -
FDA 2016/10/19 Pathway - UniProt -
EMA 2016/11/9 Remarks LARTRUVO is a drug to treat for soft tissue sarcoma (STS) in adults by nhibiting the action of Platelet-derived growth factor receptor (platelet-derived growth factor) α. It's used in combination with the chemotherapeutic agent doxorubicin. Target Protein PDGFRα
status approved Source https://www.drugs.com/pro/lartruvo.html
https://www.mixonline.jp/Article/tabid/55/artid/54740/Default.aspx		 PDB
    Concomitant Drugs doxorubicin    
R03DX05 R03D omalizumab
オマリズマブ		 XOLAIR
ゾレア		 PMDA 2009/1/21 Adaptation Diseases Atopic disease DrugBank DB00043
FDA 2003/6/20 Pathway Fc epsilon RI signaling pathway, Asthma UniProt P12319
Q01362
EMA 2005/10/25 Remarks Omalizumab inhibits mediator release in allergic reactions. It is used in combination with chlorambucil. Target Protein IgE
status approved Source http://www.medscape.com/viewarticle/779822
http://www.centerwatch.com/drug-information/fda-approved-drugs/drug/1063/xolair-omalizumab		 PDB 4X7T
4X7S
2XA7
2XA7
    Concomitant Drugs -    
- - otelixizumab - PMDA - Adaptation Diseases Type I diabetes, Psoriasis DrugBank -
FDA phase2 Pathway T cell receptor signaling pathway UniProt P04234
P07766
P09693
P20963
EMA - Remarks A Phase 3 trials for type 1 diabetic patient was conducted, but otelixizumab was not authorized, because there were no functional maintenance of pancreatic β cells which are expected effect. re-registered in 2014, a Phase 1/2 study to explore the dose tolerability has been initiated. Target Protein CD3
status phase II Source http://www.medscape.com/viewarticle/828944 PDB
    Concomitant Drugs -    
- - ozanezumab - PMDA - Adaptation Diseases ALS, Maultiple sclerosis DrugBank -
FDA phase2 Pathway - UniProt Q3LIF1
EMA - Remarks As a result of a Phase 1/2 trial to evaluate safety, pharmacokinetics, function and the effects of biomarker for patients amyotrophic lateral sclerosis, tolerability was good. A phase 2 trial has been initiated to evaluate the efficacy and safety. Target Protein Nogo-A protein
status phase II Source http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0097803
http://www.ncbi.nlm.nih.gov/pubmed/25706882		 PDB
    Concomitant Drugs -    
J06BB16 J06B palivizumab
パリビズマブ		 SYNAGIS
シナジス		 PMDA 2013/8/20 Adaptation Diseases Lower respiratory tract disease by RS virus DrugBank -
FDA 1998/6/19 Pathway - UniProt Q9P7D9
Q9Y815
EMA 1999/8/13 Remarks palivizumab is used for the treatment of RSV infection in children. Target Protein RSV F protein
status approved Source http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AntiviralDrugsAdvisoryCommittee/UCM248473.pdf PDB
    Concomitant Drugs -    
L01XC08 L01X panitumumab
パニツムマブ		 VECTIBIX
ベクティビックス		 PMDA 2010/4/16 Adaptation Diseases Colorectal cancer DrugBank DB01269
FDA 2006/9/27 Pathway MAPK signaling pathway, ErbB signaling pathway, Calcium signaling pathway, Cytokine-cytokine receptor interaction, Pathways in cancer UniProt P00533
EMA 2007/12/3 Remarks Panitumumab is metastatic colorectal cancer medicine, targeting EGFR. Target Protein EGFR
status approved Source http://www.ncbi.nlm.nih.gov/pubmed/20921465
http://www.livertox.nih.gov/Panitumumab.htm		 PDB
    Concomitant Drugs -    
- - pascolizumab - PMDA - Adaptation Diseases Asthma DrugBank -
FDA R 2003
(phase2)		 Pathway - UniProt -
EMA - Remarks Pascolizumab had been developed as an asthma remedy. Target Protein IL-4
status reject Source http://www.ncbi.nlm.nih.gov/pubmed/12296858 PDB
    Concomitant Drugs -    
L01XC18 L01X pembrolizumab
ペムブロリズマブ		 KEYTRUDA
キイトルーダ		 PMDA 2016/9/28 Adaptation Diseases BRAF mutation, Malignant melanoma DrugBank DB09037
FDA 2014/9/4 Pathway - UniProt Q15116
EMA 2015/7/17 Remarks Pembrolizumab is used for the treatment of unresectable or metastatic melanoma. There are side effects of pneumonia, colitis, hepatitis, endocrine disorders and nephritis. Target Protein PD-1
status approved Source http://www.mercknewsroom.com/news-release/prescription-medicine-news/fda-approves-expanded-indication-mercks-keytruda-pembrolizum PDB
    Concomitant Drugs -    
- - pemtumomab - PMDA - Adaptation Diseases Gastric cancer, Ovarian cancer DrugBank -
FDA R 2004
(phase3)		 Pathway - UniProt -
EMA - Remarks Pemtumomab had been developed as a topical therapeutic agent of epithelial ovarian cancer patients. Development has been aborted, because it did not show the survival and the effect of extending recurrence time of cancer in a Phase 2 study. Target Protein MUC1
status reject Source http://clincancerres.aacrjournals.org/content/17/20/6406.full.pdf
http://www.nature.com/nbt/journal/v21/n1/full/nbt0103-3a.html		 PDB
    Concomitant Drugs -    
L01XC13 L01X pertuzumab
ペルツズマブ		 PERJETA
パージェタ		 PMDA 2013/6/28 Adaptation Diseases Her2-positive inoperable cancer, Recurrent breast cancer DrugBank DB06366
FDA 2012/6/8 Pathway ErbB signaling pathway, Calcium signaling pathway, Focal adhesion, Adherens junction UniProt P04626
EMA 2013/3/4 Remarks pertuzumab is used for the treatment of HER2-positive metastatic breast cancer. Target Protein HER2
status approved Source http://www.ascopost.com/ViewNews.aspx?nid=8536 PDB 1S78
4LLU
4LLW
4LLY
4YDV
4PUB
4OGX
4OGY
4OQT
3N85
    Concomitant Drugs -    
- - pidilizumab - PMDA - Adaptation Diseases Cancer and Infectious diseases DrugBank -
FDA phase2 Pathway - UniProt Q15116
EMA - Remarks A result of a Phase 1 dose escalation study in hematological malignancies, overall safety has been confirmed. A Phase 2 trial, to evaluate the safety and efficacy against blood malignant tumors and solid tumor, has been initiated. A Phase 2 trial for diffuse large B-cell lymphoma patients after autologous stem cell transplantation has been completed. Target Protein PD-1
status phase II Source http://www.curetechbio.com/?TemplateID=29&PageID=145&TemplateType=14
http://medical.nikkeibp.co.jp/leaf/all/gakkai/sp/icml2013/201306/531258.html		 PDB
    Concomitant Drugs -    
- - polatuzumab vedotin - PMDA - Adaptation Diseases large B cell lymphoma, Non-Hodgkin's lymphoma DrugBank -
FDA phase2 Pathway - UniProt -
EMA - Remarks A Phase 1 trial for patients with relapsed or refractory B-cell non-Hodgkin's lymphoma and chronic lymphocytic leukemia had been carried out, and good results were obtained. Receiving this result, a Phase 2 trial has been initiated. Target Protein CD79b
status phase II Source http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)70128-2/fulltext?rss=yes
http://www.roche.com/investors/updates/inv-update-2014-05-31b.htm		 PDB
    Concomitant Drugs -    
- - racotumomab - PMDA - Adaptation Diseases Non-small cell lung cancer DrugBank -
FDA phase2 Pathway - UniProt -
EMA - Remarks As a result of a placebo-controlled Phase 2/3 trial, superiority was over placebo group. Target Protein NeuGcGM3
status phase II Source http://www.vaxira.com/eng/vaxira.php PDB
    Concomitant Drugs -    
L01XC21 L01X ramucirumab
ラムシルマブ		 CYRAMZA
サイラムザ		 PMDA 2015/3/26 Adaptation Diseases Malignant tumor, Solid tumors DrugBank -
FDA 2014/4/21 Pathway Cytokine-cytokine receptor interaction, VEGF signaling pathway, Focal adhesion UniProt P35968
EMA 2014/12/19 Remarks Ramucirumab is used for the treatment of metastatic colorectal cancer. There are side effects of Neutropenia, fatigue, asthenia, stomatitis and mucosal inflammation. Target Protein VEGFR2
status approved Source http://www.cancer.gov/about-cancer/treatment/drugs/fda-ramucirumab PDB
    Concomitant Drugs -    
S01LA04 S01L ranibizumab
ラニビズマブ		 LUCENTIS
ルセンティス		 PMDA 2009/1/21 Adaptation Diseases Age-related macular degeneration DrugBank DB01270
FDA 2006/6/30 Pathway Cytokine-cytokine receptor interaction, VEGF signaling pathway UniProt P15692
EMA 2007/1/22 Remarks Ranibizumab is used in the treatment of macular degeneration. In the United States, the availability has been limited from October 2007. Target Protein VEGF-A
status approved Source http://www.ncbi.nlm.nih.gov/pubmed/22330964
http://www.allaboutvision.com/conditions/lucentis-vs-avastin.htm		 PDB
    Concomitant Drugs -    
J06BB18 J06B raxibacumab RAXIBACUMAB PMDA - Adaptation Diseases Anthrax infection DrugBank -
FDA 2012/12/14 Pathway NOD-like receptor signaling pathway UniProt P40136
P15917
EMA - Remarks Raxibacumab is used for the treatment of infection by anthrax inhalation, targeting B.anthracis toxin. Target Protein B.anthracis toxin
status approved Source https://clinicaltrials.gov/ct2/show/NCT02177721
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm332341.htm		 PDB
    Concomitant Drugs -    
R03DX08 R03D reslizumab CINQAIR (CINQAERO) PMDA - Adaptation Diseases Bronchial asthma DrugBank -
FDA 2016/3/23 Pathway Cytokine-cytokine receptor interaction, Jak-STAT signaling pathway UniProt P05113
EMA 2016/8/16 Remarks As a result of four independent placebo-controlled phase 3 clinical trials for the asthma patient, the asthma exacerbation rate greatly reduced and significantly improved lung function and other secondary measures. Target Protein IL-5
status approved Source http://www.tevapharm.com/news/teva_announces_fda_acceptance_of_the_biologics_license_application_for_reslizumab_06_15.aspx
http://www.teva.jp/news/2014/pdf/0908.pdf		 PDB
    Concomitant Drugs -    
L04AC04 L04A rilonacept ARCALYST
RILONACEPT REGENERON		 PMDA - Adaptation Diseases CAPS DrugBank DB06372
FDA 2008/2/27 Pathway MAPK signaling pathway, Cytokine-cytokine receptor interaction, Apoptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway UniProt P14778
EMA 2009/10/23
W		 Remarks Rilonacept is used in treatment of the cryopyrin associated periodic fever syndrome (CAPS), including the familial cold urticaria (FCAS) and Muckle-Wells syndrome (MWS), The target is IL-1 which is over-produced in the body, Target Protein IL-1R1
status approved Source http://www.medscape.com/viewarticle/763520 PDB
    Concomitant Drugs -    
- - rilotumumab - PMDA - Adaptation Diseases Solid tumors DrugBank -
FDA R 2014
(phase3)		 Pathway Cytokine-cytokine receptor interaction, Focal adhesion, Pathways in cancer UniProt P08581
EMA - Remarks In a phase 3 trial, the number of deaths of chemotherapy combination group was higher than chemotherapy alone group. As a result of the safety evaluation of the trial, development of rilotumumab was discontinued. Target Protein HGF
status reject Source https://www.astellas.com/jp/corporate/news/pdf/141125_j_news.pdf PDB
    Concomitant Drugs -    
L01XC02 L01X rituximab
リツキシマブ		 RITUXAN, MabTHERA
リツキサン		 PMDA 2001/6/20 Adaptation Diseases Malignant tumor DrugBank DB00073
FDA 1997/11/26 Pathway Hematopoietic cell lineage UniProt P11836
EMA 1998/6/2 Remarks Rituximab is used for the treatment of B cell non-Hodgkin's lymphoma. At the first administration, sometimes allergic symptoms such as itching fever and chills appear. As serious side effects, bone marrow suppression and heart failure, interstitial pneumonia, renal failure, cranial nerve disorders have been confirmed. The trial for adaptation to arthritis and non-Hodgkin's lymphoma has been initiated. Target Protein CD20
status approved Source http://www.anticancer-drug.net/molecular/rituximab.htm
http://www.gabionline.net/Biosimilars/News/Amgen-starts-phase-III-trial-for-biosimilar-rituximab		 PDB 4KAQ
2OSL
1L6X
2IWG
2WAH
4ACP
4B71
2J6E
    Concomitant Drugs -    
- - romiplostim NPLATE PMDA - Adaptation Diseases immune thrombo-cytopenic purpura DrugBank -
FDA 2008/8/22 Pathway Cytokine-cytokine receptor interaction, Jak-STAT signaling pathway UniProt P40238
EMA - Remarks Romiplostim is the medicine of chronic idiopathic thrombocytopenic purpura, targeting TPOR (thrombopoietin receptor). Target Protein TPOR
status approved Source http://www.cancernetwork.com/hematologic-malignancies/road-romiplostim-approval-and-beyond
https://www.anthem.com/medicalpolicies/policies/mp_pw_c166598.htm
http://www.medicines.ie/medicine/14435/SPC/Nplate/		 PDB
    Concomitant Drugs -    
- - romosozumab - PMDA - Adaptation Diseases Osteoporosis DrugBank -
FDA phase3 Pathway Wnt signaling pathway UniProt Q9BQB4
EMA - Remarks As a result of Phase 2 study for osteoporotic postmenopausal patients, the bone density increased significantly. A Phase 3 trial has been initiated in 2014. Target Protein sclerostin
status phase III Source http://www.ucb.com/investors/UCB-tomorrow/romosozumab
http://www.aabp.co.jp/en/news/?newsid=D69B4A687F9A4AD1A6D425E434392883
http://www.aabp.co.jp/jp/news/?newsid=D69B4A687F9A4AD1A6D425E434392883		 PDB
    Concomitant Drugs -    
- - sacituzumab govitecan - PMDA - Adaptation Diseases Breast cancer, Solid tumors DrugBank -
FDA phase2 Pathway - UniProt -
EMA - Remarks A Phase 2 study for Patients with metastatic lung cancer and small cell lung cancer has been carried out. Target Protein DNA topoisome-rase I
TROP2
status phase II Source http://adcreview.com/news/sacituzumab-govitecan-immu-132-shows-positive-interim-phase-ii-results/
https://globenewswire.com/news-release/2015/09/08/766568/10148455/en/Immunomedics-Reports-Interim-Phase-2-Results-With-Sacituzumab-Govitecan-in-Lung-Cancers.html		 PDB
    Concomitant Drugs -    
V09IB02 V09I satumomab Indium (111In) satumomab pendetide PMDA - Adaptation Diseases Rheumatoid arthritis, Ankylosing spondylitis DrugBank -
FDA - Pathway Cytokine-cytokine receptor interaction, Jak-STAT signaling pathway UniProt P05231
EMA - Remarks As a result of a Phase 3 trial, rheumatoid arthritis and physical function was improved. Biologics license application (BLA) has been carried out against FDA. Target Protein IL-6
status phase III Source http://www.prnewswire.com/news-releases/regeneron-and-sanofi-present-results-from-pivotal-phase-3-study-of-sarilumab-at-american-college-of-rheumatology-annual-meeting-300174459.html
http://www.sanofi.co.jp/l/jp/ja/layout.jsp?cnt=CBF43346-DF63-4A07-87E3-AD403FBEB056
http://www.qlifepro.com/news/20131209/sanofi-and-regeneron-inc-sarilumab-no-positive-phase-iii-trial-results-announced.html		 PDB
    Concomitant Drugs -    
L04AC10 L04A secukinumab
セクキヌマブ		 COSENTYX
コセンティクス		 PMDA 2014/12/26 Adaptation Diseases Uveitis, Rheumatoid arthritis, psoriasis DrugBank DB09029
FDA 2015/1/21 Pathway Cytokine-cytokine receptor interaction, Rheumatoid arthritis UniProt Q16552
EMA 2015/1/15 Remarks secukinumab is used for the treatment of aspect type psoriasis of moderate or severe, targeting IL-17A. Target Protein IL-17A
status approved Source http://www.novartis.co.jp/news/2013/pr20130718.html
https://www.novartis.com/news/media-releases/novartis-announces-fda-approval-first-il-17a-antagonist-cosentyxtm-secukinumab		 PDB
    Concomitant Drugs -    
L04AC11 L04A seribantumab - PMDA - Adaptation Diseases Breast cancer, Non-small cell lung cancer, Ovarian cancer DrugBank -
FDA phase2 Pathway - UniProt -
EMA - Remarks A randomized, open-label Phase 2 study for the HER2-negative breast cancer patients was carried out. It compared the chemotherapy + trastuzumab and MM-302 + trastuzumab hormone receptor-positive. The trial results were good. Target Protein ERBB3
status phase II Source http://investors.merrimack.com/releasedetail.cfm?releaseid=887436 PDB
    Concomitant Drugs -    
- - sifalimumab - PMDA - Adaptation Diseases SLE, Dermatomyositis, Polymyositis DrugBank -
FDA R 2015
(phase2)		 Pathway Cytokine-cytokine receptor interaction, Regulation of autophagy UniProt -
EMA - Remarks Sifalimumab had been developed as systemic lupus erythematosus, dermatomyositis and polymyositis of medicine. In a Phase 2b trial, it had achieved the primary endpoint. Target Protein interferon α
status reject Source http://acrabstracts.org/abstract/safety-and-efficacy-of-sifalimumab-an-anti-ifn-alpha-monoclonal-antibody-in-a-phase-2b-study-of-moderate-to-severe-systemic-lupus-erythematosus-sle/ PDB
    Concomitant Drugs -    
L04AC11 L04A silutuximab SYLVANT PMDA - Adaptation Diseases Castleman's disease DrugBank DB09036
FDA 2014/4/23 Pathway Cytokine-cytokine receptor interaction, Jak-STAT signaling pathway UniProt P05231
EMA 2014/5/22 Remarks Silutuximab is used for the treatment of early multiple myeloma (MM), targeting IL-6. Target Protein IL-6
status approved Source http://www.bloodjournal.org/content/123/26/4136?sso-checked=true
http://www.ascopost.com/issues/june-25,-2014/fda-approval-of-siltuximab-for-multicentric-castleman%E2%80%99s-disease.aspx		 PDB
    Concomitant Drugs -    
- - simtuzumab - PMDA - Adaptation Diseases Hepatic fibrosis, Idiopathic pulmonary fibrosis, Liver cirrhosis, Non-alcoholic steatohepatitis, Primary sclerosing cholangitis DrugBank -
FDA phase2 Pathway - UniProt -
EMA - Remarks Gemcitabine combination study at a Phase 2 trial for untreated advanced pancreatic cancer patients was carried out. Target Protein CXCL12
LOXL2
VEGF-A
status phase II Source http://www.gilead.com/news/press-releases/2014/9/gilead-announces-data-from-phase-2-study-of-simtuzumab-for-previously-untreated-pancreatic-cancer PDB
    Concomitant Drugs -    
- - sirukumab - PMDA - Adaptation Diseases Rheumatoid arthritis DrugBank -
FDA phase3 Pathway Cytokine-cytokine receptor interaction, Jak-STAT signaling pathway UniProt P05231
EMA - Remarks As a result of a Phase 3 trials in patients with rheumatoid arthritis, signs and symptoms that were indicated in the primary endpoint has been improved. Target Protein IL-6
status phase III Source http://www.bioworld.com/content/sirukumab-enters-phase-iii-rheumatoid-arthritis-study-0 PDB
    Concomitant Drugs -    
- - solanezumab - PMDA - Adaptation Diseases Alzheimer's disease DrugBank -
FDA phase3 Pathway - UniProt P05067
EMA - Remarks a Phase 3 trial has been carried out for Alzheimer's disease patients. Trial results will be announced in early December 2016. Target Protein β-amyloid
status phase III Source http://www.alzforum.org/therapeutics/solanezumab PDB
    Concomitant Drugs -    
V09HA04 V09H sulesomab LEUKOSCAN PMDA - Adaptation Diseases Diabetic foot ulcer, Osteomyelitis (bone infection) DrugBank -
FDA - Pathway - UniProt -
EMA 1997/2/14 Remarks Sulesomab is used as an imaging means for diabetic foot ulcers and osteomyelitis. It's labeled with 99mTc before use. Target Protein NCA90
status approved Source http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000111/WC500036473.pdf PDB
    Concomitant Drugs -    
- - tabalumab - PMDA - Adaptation Diseases Autoimmune diseases, B cell malignancies DrugBank -
FDA R 2015
(phase2)		 Pathway Cytokine-cytokine receptor interaction UniProt -
EMA - Remarks Because the utility was not observed, the trial was aborted in a Phase 3 trial Safety concerns did not exist. Target Protein BAFF
status reject Source http://mf.jiho.jp/servlet/nk/kigyo/article/1226571962519.html?pageKind=outline
https://investor.lilly.com/releasedetail.cfm?ReleaseID=874281		 PDB
    Concomitant Drugs -    
- - tanezumab - PMDA - Adaptation Diseases Back pain, Cancer pain, Musculoskeletal pain, Pain DrugBank -
FDA phase3 Pathway MAPK signaling pathway, Apoptosis, Neurotrophin signaling pathway UniProt P01138
EMA - Remarks As a result of a Phase 2 trial for patients with severe to moderate knee osteoarthritis, a substantial improvement in symptoms was observed. A phase 3 trial has been initiated. Target Protein NGF
status phase III Source https://www.ucdmc.ucdavis.edu/publish/news/newsroom/4365
http://www.pfizer.com/news/press-release/press-release-detail/pfizer_and_lilly_preparing_to_resume_phase_3_chronic_pain_program_for_tanezumab		 PDB
    Concomitant Drugs -    
- - tarextumab - PMDA - Adaptation Diseases Pancreatic cancer, Small cell lung cancer DrugBank -
FDA phase2 Pathway - UniProt -
EMA - Remarks A result of a Phase 1b trial, to verify Maximal tolerated dose (MTD), pharmacokinetics (PK) and pharmacodynamics (PD), showed that Promising antitumor activity had been observed. A randomized, placebo-controlled Phase 2 trial has been initiated. Target Protein Notch-2 receptor
Notch-3 receptor
status phase II Source http://meetinglibrary.asco.org/content/153399-156
http://www.oncomed.com/Pipeline.html		 PDB
    Concomitant Drugs -    
- - tildrakizumab - PMDA - Adaptation Diseases Plaque psoriasis DrugBank -
FDA phase3 Pathway - UniProt Q9NPF7
EMA - Remarks As a result of a randomized and double-blind Phase 2b study for chronic plaque psoriasis patients with moderate to severe, it showed excellent therapeutic effect than the placebo group. A Phase 3 trial has been initiated. Target Protein IL-23
status phase III Source http://www.ncbi.nlm.nih.gov/pubmed/26042589 PDB
    Concomitant Drugs -    
- - tilmanocept Lymphoseek PMDA - Adaptation Diseases Breast cancer, Head and neck cancer, Malignant melanoma DrugBank -
FDA 1905/7/5 Pathway - UniProt -
EMA 1905/7/6 Remarks Tilmanocept is used as an imaging means for patients with breast cancer and melanoma. It's labeled with 99mTc before use. Target Protein
status approved Source http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3560941/
http://ir.navidea.com/phoenix.zhtml?c=68527&p=irol-newsArticle&ID=1795818		 PDB
    Concomitant Drugs -    
L04AC07 L04A tocilizumab
トシリズマブ		 ACTEMRA (RoActemra)
アクテムラ		 PMDA 2008/4/16 Adaptation Diseases Castleman's disease, Multiple myeloma, Systemic lupus erythematosus, Crohn's disease, Rheumatoid arthritis, Systemic juvenile idiopathic arthritis DrugBank DB06273
FDA 2010/1/8 Pathway Cytokine-cytokine receptor interaction, Jak-STAT signaling pathway, Hematopoietic cell lineage UniProt P08887
EMA 2009/1/16 Remarks Tocilizumab is used for the treatment of rheumatoid arthritis, targeting the IL-6 over-expressed in the body. Because it is impossible to cure completely, long-term administration is necessary. Target Protein IL-6R
status approved Source http://www.drugdevelopment-technology.com/projects/actemra/ PDB
    Concomitant Drugs -    
V10XA53 V10X tositumomab BEXXAR PMDA - Adaptation Diseases Non-Hodgkin's lymphoma DrugBank DB00081
FDA 2003/6/27 Pathway Hematopoietic cell lineage UniProt P11836
EMA - Remarks Tositumomab is a refractory follicular non-Hodgkin's lymphoma treatment drugs, targeting CD20. In February 2014, the maker had discontinued manufacturing. Target Protein CD20
status approved Source http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721297/
http://www.cancer.gov/about-cancer/treatment/drugs/fda-tositumomab-I131iodine-tositumomab		 PDB
    Concomitant Drugs -    
- - tralokinumab - PMDA - Adaptation Diseases Asthma, Inflammatory diseases DrugBank -
FDA phase3 Pathway Cytokine-cytokine receptor interaction, Jak-STAT signaling pathway UniProt P35225
EMA - Remarks Received the results of a Phase 2b trial, a Phase 3 trial is currently carried out in severe or uncontrolled asthma patients. The test evaluats safety and efficacy. Target Protein IL-13
status phase III Source https://www.astrazeneca.com/our-company/media-centre/articles/astrazeneca-personalised-healthcare-13052015.html
https://www.astrazeneca.com/our-company/media-centre/press-releases/2014/astrazeneca-tralokinumab-treatment-severe-asthma-14082014.html
http://www.astrazeneca.co.jp/media/pressrelease/Article/201505182		 PDB
    Concomitant Drugs -    
L01XC03 L01X trastuzumab
トラスツズマブ		 HERCEPTIN
ハーセプチン		 PMDA 2001/4/4 Adaptation Diseases Metastatic breast cancer DrugBank DB00072
FDA 1998/9/25 Pathway ErbB signaling pathway, Focal adhesion, Adherens junction, Pathways in cancer UniProt P04626
EMA 2000/8/28 Remarks Trastuzumab is used for the treatment of HER2-positive metastatic breast cancer. There are side effects of Headache, asthenia, nausea and vomiting. Target Protein HER2
status approved Source http://www.gene.com/media/product-information/herceptin-development-timeline PDB 4HJG
4IOI
4HKZ
1S78
    Concomitant Drugs -    
L01XC14 L01X trastuzumab emtansine
トラスツズマブ　エムタンシン		 KADCYLA
カドサイラ		 PMDA 2013/9/20 Adaptation Diseases Her2-positive inoperable cancer, Recurrent breast cancer DrugBank DB05773
FDA 2013/2/22 Pathway ErbB signaling pathway, Calcium signaling pathway, Focal adhesion, Adherens junction, Pathways in cancer UniProt P04626
EMA 2013/11/15 Remarks Trastuzumab emtansine is used for the treatment of HER2-positive metastatic or recurrent breast cancer. Its components are Trastuzumab which treat breast cancer and tubulin polymerization inhibitor DM1 with cytotoxic , is an antibody drug conjugate. After binding to the target, DM1 is delivered to the inside of the cancer cells, to destroy the cell. Target Protein HER2
status approved Source http://www.chugai-pharm.co.jp/hc/ss/downloads/130129jT-DM1.pdf?blobheader=application%2Fpdf&blobheadername1=content-disposition&blobheadervalue1=inline%3Bfilename%3D130129jT-DM1.pdf&blobwhere=1396858140824&ssbinary=true
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4206612/		 PDB
    Concomitant Drugs -    
- - tremelimumab - PMDA - Adaptation Diseases Melanoma DrugBank -
FDA phase3 Pathway Cell adhesion molecules (CAMs), T cell receptor signaling pathway UniProt P16410
EMA - Remarks In a Phase 1/2 study for the advanced melanoma patients, durability response was observed. A Phase 3 trial, for advanced melanoma patients, had been carried out to evaluate the endpoints of safety and efficacy in comparison with chemotherapy. As a result, the survival benefit advantage against chemotherapy did not show. Target Protein CTLA4
status phase III Source https://www.astrazeneca.com/our-company/media-centre/articles/immuno-oncology-update-european-cancer-congress-24092015.html
http://www.astrazeneca.co.jp/media/pressrelease/Article/201504172		 PDB
    Concomitant Drugs -    
L04AC05 L04A ustekinumab
ウステキヌマブ		 STELARA
ステラーラ		 PMDA 2011/1/21 Adaptation Diseases Plaque psoriasis, Psoriatic arthritis DrugBank DB05679
FDA 2009/9/25 Pathway Cytokine-cytokine receptor interaction, Jak-STAT signaling pathway UniProt P42701
Q9NPF7
EMA 2009/1/16 Remarks Ustekinumab is used in the treatment of psoriasis vulgaris and joint disease psoriasis. The targets are IL-12 and IL-23-p40. Target Protein IL-12
IL-23-p40
status approved Source http://mcgs.bcbsfl.com/?doc=Ustekinumab%20(Stelara%20TM) PDB 3HMW
3HMX
    Concomitant Drugs -    
- - vantictumab - PMDA - Adaptation Diseases advanced solid tumor, HER2-negative breast cancer DrugBank -
FDA phase1b Pathway Wnt cancer stem cell pathway UniProt -
EMA - Remarks As a result of Phase 1b trial for patients with advanced non-small cell lung cancer (NSCLC), HER2-negative breast cancer and advanced pancreatic cancer, the risk of adverse events has been suggested. Reduced the registration items, it has been made the trial again. Target Protein Frizzled receptors
status phase I Source http://investor.shareholder.com/oncomed/releasedetail.cfm?ReleaseID=868147
http://globenewswire.com/news-release/2015/11/09/785208/0/en/OncoMed-Presents-Data-From-Brontictuzumab-Vantictumab-and-Anti-DLL4-VEGF-Bispecific-Programs-at-the-AACR-NCI-EORTC-International-Conference-on-Molecular-Targets-and-Cancer-Therapeu.html		 PDB
    Concomitant Drugs -    
L04AA33 L04A vedolizumab ENTYVIO PMDA - Adaptation Diseases Ulcerative colitis, Crohn's disease DrugBank DB09033
FDA 2014/5/20 Pathway ECM-receptor interaction, Cell adhesion molecules (CAMs) UniProt P13612
P26010
EMA 2014/5/22 Remarks Vedolizumab is used for the treatment of severe Crohn's disease and moderate or severe ulcerative colitis. The target is integrin α4β7. Target Protein integrin α4β7
status approved Source http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3557917/
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm398065.htm		 PDB
    Concomitant Drugs -    
- - veltuzumab - PMDA - Adaptation Diseases Non-Hodgkin's lymphoma DrugBank -
FDA phase2 Pathway Hematopoietic cell lineage UniProt P11836
EMA - Remarks a Phase 1/2 trial, for idiopathic thrombocytopenic purpura (ITP) and chronic lymphocytic leukemia (CLL) patients, has been carried out. Target Protein CD20
status phase II Source http://www.immunomedics.com/veltuzumab.shtml PDB
    Concomitant Drugs -    
V09IA04 V09I votumumab HumaSPECT PMDA - Adaptation Diseases Colorectal cancer DrugBank -
FDA - Pathway - UniProt -
EMA 1998/9/25
W		 Remarks Biomedix Co. Ltd. did not renew a marketing authorization of votumumab in the commercial reasons. Approval has expired in September 2003. Target Protein CTAA16.88
status withdraw Source http://www.ema.europa.eu/docs/en_GB/document_library/Public_statement/2009/12/WC500018374.pdf PDB
    Concomitant Drugs -    
- - yttrium (90Y) clivatuzumab tetraxetan - PMDA - Adaptation Diseases Pancreatic cancer DrugBank -
FDA phase3 Pathway - UniProt P15941
EMA - Remarks Gemcitabine combination study at a Phase 1/2b trial for stage III or IV pancreatic cancer patients, good results were obtained. A Phase 3 trial has been initiated. Target Protein CD227
status phase III Source http://www.immunomedics.com/clivatuzumab.shtml PDB
    Concomitant Drugs -    
- - - IMC gp100 PMDA - Adaptation Diseases Malignant melanoma DrugBank -
FDA phase2 Pathway - UniProt -
EMA - Remarks A durvalumab and tremelimumab combination study at a Phase 1/2b trial for refractory metastatic cutaneous melanoma patients has been initiated Target Protein CD3
status phase II Source https://clinicaltrials.gov/ct2/show/NCT02535078 PDB
    Concomitant Drugs -    
- - - IPH2201 PMDA - Adaptation Diseases Head and neck cancer DrugBank -
FDA phase2 Pathway - UniProt -
EMA - Remarks A Phase 2 study, in combination with MEDI473 under phase 3 trials for solid tumor, has been initiated. Target Protein NK cell lectin-like receptor subfamily C
status phase II Source https://www.astrazeneca.com/our-company/media-centre/press-releases/2015/astrazeneca-innate-pharma-global-collaboration-immuno-oncology-24042015.html PDB
    Concomitant Drugs -    
- - - LY2928057 PMDA - Adaptation Diseases Anaemia DrugBank -
FDA phase1 Pathway - UniProt -
EMA - Remarks Phase 1 trial to measure the effect on blood hemoglobin have been initiated. Target Protein Cation transport protein
status phase I Source https://clinicaltrials.gov/ct2/show/NCT01991483
http://adisinsight.springer.com/drugs/800003245
http://www.bloodjournal.org/content/122/21/3433?sso-checked=true		 PDB
    Concomitant Drugs -    
- - - LY3002813 PMDA - Adaptation Diseases Alzheimer's disease DrugBank -
FDA phase1 Pathway - UniProt -
EMA - Remarks A Phase 1 trial for mild Alzheimer's disease and mild cognitive impairment patients has been started from May 2013. Target Protein β-amyloid
status phase I Source http://www.alzforum.org/therapeutics/ly3002813 PDB
    Concomitant Drugs -    
- - - MABp1 PMDA - Adaptation Diseases Cachexia, Colorectal cancer DrugBank -
FDA phase3 Pathway - UniProt -
EMA - Remarks As a result of Phase I trial for 52 people with metastatic patients, dose-limiting toxicity and immunogenicity was well tolerated. Target Protein IL-1α
status phase III Source http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70155-X/fulltext PDB
    Concomitant Drugs -    
- - - MEDI-551 PMDA - Adaptation Diseases Neuromyelitis optica DrugBank -
FDA phase3 Pathway - UniProt -
EMA - Remarks A Phase 3 trial for refractory chronic lymphocytic leukemia (CLL) patients has been carried out. In the trial, superiority in excess of Rituximab is investigated. Target Protein CD19
status phase III Source https://clinicaltrials.gov/ct2/show/NCT01466153 PDB
    Concomitant Drugs -    
- - - MEDI4736 PMDA - Adaptation Diseases Non-small cell lung cancer, Head and neck cancer DrugBank -
FDA phase3 Pathway - UniProt -
EMA - Remarks Currently, a Phase 3 trial for non-small cell lung cancer and head and neck cancer has been carried out. The development in all clinical trials is led by CELGENE CORP from April 2015. Target Protein PD-L1
status phase III Source http://www.astrazeneca.co.jp/media/pressrelease/Article/201505082
http://www.jpma.or.jp/medicine/shinyaku/development/com0030.html		 PDB
    Concomitant Drugs -